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ABSTRACT 
 
 Current estimates suggest that as many as 9% of Americans meet the 
DSM-IV criteria for substance use disorders, and the annual economic burden of 
substance abuse has been assessed at approximately half a trillion dollars. Thus, 
addiction is a highly prevalent social problem that rivals almost any other public 
health issue in terms of social and personal costs. However, despite the fact that 
addiction is significantly heritable, very few specific genetic susceptibility factors 
have been reliably identified. Moreover, even for the most promising risk genes, 
the systems-level neural mechanisms that mediate their impact on risk are 
largely unknown. In this dissertation, I use a dual-scan dopamine receptor 
imaging approach with the stimulant drug amphetamine to probe the 
neurogenetic architecture of addiction. Motivated by the key role played by 
dopamine in drug addiction, I test the hypothesis that genetic variability in three 
distinct brain signaling systems with conceptual links to addiction converge to 
exert a sensitizing effect on striatal dopamine responses to drugs of abuse. First, 
I examine variation at a locus in the CSNK1E gene, which encodes a protein 
kinase that regulates the function of the dopamine signaling integrator DARPP-
32. Second, I study an allelic variant in the gene encoding an hypothalamic-
pituitary-adrenal (HPA) stress axis factor (CRH) that has been previously 
associated with stress-induced alcohol consumption in non-human primates. 
Finally, given the prominent psychopathological and neurobiological parallels 
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between obesity and addiction, I investigate the novel hypothesis that obesity-
linked genetic variability in leptin signaling (LEPR) may predispose risk for 
substance abuse by affecting striatal dopamine responses to stimulants. In all 
cases, individuals who carried the putative risk allele at each of these loci 
demonstrated marked sensitization of striatal dopamine responses to 
amphetamine. In turn, the magnitude of striatal dopamine release was positively 
associated with subjective responses to amphetamine and with individual 
differences in impulsivity. Taken together, these findings support the involvement 
of two genes (CSNK1E and CRH) in risk for addiction, nominate a third (LEPR) 
for enhanced phenotypic investigation, and offer a common neurobiological 
mechanism – sensitization of striatal dopaminergic function – that may be 
involved in the conferral of susceptibility by diverse genetic risk factors.   
 
 
   
 
 viii 
TABLE OF CONTENTS 
 
 
 
ACKNOWLEDGEMENTS............................................................................... iii 
 
ABSTRACT ....................................................................................................vi 
 
LIST OF TABLES ...........................................................................................xi 
 
LIST OF FIGURES........................................................................................ xii 
 
Chapter 
 
 I. INTRODUCTION...................................................................................... 1 
  
  Individual Differences in Addiction Liability: Genetic Mechanisms .......... 1 
  Addiction as a Disease of Reward and Motivation................................... 3 
  Human Mesolimbic DA Function and Addiction Risk ............................... 8 
  Specific Aims.......................................................................................... 13 
 
 II. ALLELIC VARIATION IN THE DOPAMINE REGULATING GENE 
CSNK1E SENSITIZES STIMULANT-INDUCED STRIATAL DOPAMINE 
RELEASE................................................................................................. 16 
  
  Methods ................................................................................................. 23 
   Participants...................................................................................... 23 
   Genotyping ...................................................................................... 24 
   PET.................................................................................................. 25 
    Image Acquisition and Analysis ................................................ 25 
    Binding Potential Maps ............................................................. 28 
    Region of Interest Analyses ...................................................... 29 
    Measurement of Subjective Response to AMPH...................... 30 
   Statistical Analysis........................................................................... 31 
  Results .................................................................................................. 32 
    Descriptive and Inferential Statistics for VS BPND .................... 32 
    CSNK1E genotype Effect on VS DA release ............................ 33 
    Whole Brain Exploratory Analysis ............................................. 34 
    CSNK1E Genotype Effect on Subjective Responses to AMPH 
    .................................................................................................. 35 
    VS DA Release Predicts Subjective Responses to AMPH ....... 35 
  Discussion.............................................................................................. 36 
     
 III. GENETIC VARIABILITY IN HPA-AXIS FUNCTION ALTERS HUMAN 
STRIATAL DOPAMINERGIC REACTIVITY ............................................ 44 
 
  ix 
  Methods ................................................................................................. 49 
   Participants...................................................................................... 49 
   Genotyping ...................................................................................... 50 
   PET.................................................................................................. 51 
    Image Acquisition and Analysis ................................................ 51 
    Binding Potential Maps ............................................................. 54 
    Region of Interest Analyses ...................................................... 55 
   Personality Measures ...................................................................... 57 
   Statistical Analysis........................................................................... 58 
  Results .................................................................................................. 60 
   Descriptive and Inferential Statistics for VS BPND ........................... 60 
   CRH Genotype Effect on VS DA Release ....................................... 61 
   Striatal Subregional Specificity of CRH Effects ............................... 62 
   Whole Brain Exploratory Analysis ................................................... 62 
Relationships between CRH Genotype, Impulsive Traits, and DA 
Release ........................................................................................... 63 
  Discussion.............................................................................................. 64 
   
 IV. OBESITY-LINKED GENETIC VARIABILITY IN LEPTIN SIGNALING 
PREDICTS ALTERATIONS IN MESOLIMBIC DOPAMINE 
NEUROCHEMISTRY ............................................................................ 70 
 
  Methods ................................................................................................. 78 
   Participants...................................................................................... 78 
   Genotyping ...................................................................................... 79 
   PET.................................................................................................. 81 
    Image Acquisition and Analysis ................................................ 81 
    Binding Potential Maps ............................................................. 83 
    Region of Interest Analyses ...................................................... 85 
   Personality Measures ...................................................................... 86 
   Statistical Analysis........................................................................... 87 
  Results .................................................................................................. 90 
   Descriptive and Inferential Statistics for VS BPND ........................... 90 
   LEPR Genotype Effect on VS DA Release ..................................... 91 
   Striatal Subregional Specificity of LEPR Genotype Effects ............. 92 
   Whole Brain Exploratory Analysis ................................................... 92 
   LEPR Genotype and Impulsive Temperament ................................ 94 
LEPR Genotype, Striatal DA Release and Impulsivity: Mediation 
Analyses .......................................................................................... 95 
  Discussion.............................................................................................. 97 
    
 V. SUMMARY AND CONCLUSION................................................... 106 
 
 General discussion............................................................................... 111 
 Limitations and Future directions ......................................................... 119 
  References........................................................................................... 131 
 x 
LIST OF TABLES 
 
 
 
Chapter 
 
 II.  ALLELIC VARIATION IN THE DOPAMINE REGULATING GENE 
CSNK1E SENSITIZES STIMULANT-INDUCED STRIATAL DA 
RELEASE 
  
  1. Demographic information for CSNK1E PET Sample ...................... 24 
   
 III.  GENETIC VARIABILITY IN HPA-AXIS FUNCTION ALTERS HUMAN 
STRIATAL DOPAMINERGIC REACTIVITY 
 
  1. Demographic information for CRH PET Sample ............................ 50 
   
 IV. OBESITY-LINKED GENETIC VARIABILITY IN LEPTIN SIGNALING 
PREDICTS ALTERATIONS IN MESOLIMBIC DOPAMINE 
NEUROCHEMISTRY 
 
  1. Demographic information for LEPR PET Sample............................ 79 
 
 
  xi 
LIST OF FIGURES 
 
 
 
Chapter 
 
 I. INTRODUCTION 
  
  1. Endophenotypes can aid in the characterization of genetic 
pathomechanisms for psychiatric illness .......................................... 3 
 
 II. ALLELIC VARIATION IN THE DOPAMINE REGULATING GENE 
CSNK1E SENSITIZES STIMULANT-INDUCED STRIATAL DA RELEASE 
 
  1. CK1e regulates phosphorylation of DARPP-32 at Ser137 ................ 20 
  2. Striatal Regions of Interest (ROIs) .................................................. 30 
  3. Amphetamine significantly reduced [18F]fallypride binding potential 
in ventral striatum ............................................................................ 33 
  4. Effects of CSNK1E rs135745 genotype on AMPH-induced DA 
release  ........................................................................................... 34 
  5. CK1e phosphorylation is necessary for the proteasomal degradation 
of PER2 ........................................................................................... 39 
  6. Exonic structure and genomic context of CSNK1E gene ............... 40 
  
 III. GENETIC VARIABILITY IN HPA-AXIS FUNCTION ALTERS HUMAN 
STRIATAL DOPAMINERGIC REACTIVITY 
 
  1. Striatal Regions of Interest (ROIs) .................................................. 56 
  2. Amphetamine significantly reduces [18F]fallypride binding potential 
in ventral striatum ............................................................................ 60 
  3. Effects of CRH rs6999100 genotype on AMPH-induced DA  
   release ............................................................................................ 61 
  3. Exonic structure and genomic context of CRH gene ...................... 67 
 
 
 IV. OBESITY-LINKED GENETIC VARIABILITY IN LEPTIN SIGNALING 
PREDICTS ALTERATIONS IN MESOLIMBIC DOPAMINE 
NEUROCHEMISTRY 
 
  1. Striatal Regions of Interest (ROIs). ................................................. 86 
  2. Amphetamine significantly reduced [18F]fallypride binding potential 
in ventral striatum ............................................................................ 90 
 3. Effects of LEPR rs1137100 genotype on AMPH-induced DA  
  Release .......................................................................................... 91 
  4. Distributions of BMI values ............................................................. 94 
   
 xii 
5. Striatal dopamine sensitization mediates the impact of LEPR  
 genotype on impulsivity ................................................................... 97 
  6. Segment of the LEPR gene on chr.1 that includes exons 4-6....... 100 
    
V. SUMMARY AND CONCLUSION 
 
 1. Genetic complexity of taxonomic disorders ................................... 128 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  1 
CHAPTER I 
 
INTRODUCTION 
 
 Current estimates suggest that as many as 9% of Americans meet the 
DSM-IV criteria for substance use disorders1, 2, and the annual economic burden 
of substance abuse including costs relating to crime, lost productivity, treatment, 
incarceration and law enforcement) has been assessed at approximately half a 
trillion dollars3. Thus, addiction is a highly prevalent social problem that rivals 
almost any other public health issue in terms of the magnitude of fiscal damage 
that it wreaks on society. Therefore, understanding the etiology and the 
pathophysiology of drug dependence represents a major target for scientific 
investigation and intervention. It is noteworthy that despite the fact that all drugs 
of abuse are highly reinforcing, only a relatively small percentage of individuals 
exposed to these drugs go on to develop the destructive pattern of compulsive 
drug seeking and drug taking that is the hallmark of addiction4. Characterizing 
sources of individual differences in risk and elucidating their mechanisms of 
action will aid in the identification of novel therapeutic targets for addiction; as 
such, these research aims represent crucial next steps in advancing treatment 
options for individuals afflicted with substance use disorders.   
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Individual Differences in Addiction Liability: Genetic Mechanisms 
 
 In considering the etiology of drug addiction, clues can be gleaned from 
heritability studies in twin and family samples that include addicted individuals. 
On the whole, such studies converge to suggest that genetic factors account for 
approximately 50% of the population variance in risk for addiction, with heritability  
(h2) estimates ranging from .4-.6, depending on the specific addictive agent 5, 6. 
The known heritability of addiction raises two questions: 1) which specific genes 
are involved in predisposing risk, and 2) what are the specific neurobiological 
pathomechanisms through which genetic risk factors exert their effects. To 
address the first question, investigators have mounted a nearly 20-year search 
for genetic associations to addiction. However, it must be said that the endeavor 
has, to date, yielded precious little fruit: though some potentially promising risk 
genes have been identified, non-replications are more the rule than the exception 
in this literature. These inconsistent genetic associations across studies likely 
result from the use of taxonomic, clinical diagnosis as a phenotypic end-point.  
However, it has been recognized that the likelihood that any given individual with 
a certain genotype will express a putatively associated phenotype (genetic 
“penetrance”) varies depending on the type of phenotype under investigation. 
This suggests that we may be able to accelerate the process of gene finding and 
pathomechanism characterization by identifying and employing more penetrant 
phenotypes.  
Crucially, compared to diagnostic or behavioral phenotypes, penetrance is 
generally greater for so-called “endophenotypes” – phenotypes that are closer to 
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the level of a variant’s direct physiological effect7-9. Practically, this means that 
significantly larger effect sizes are observed for genetic effects on 
endophenotypes – particularly systems-level biological endophenotypes – 
relative to those seen for clinical diagnosis or self-reported traits9. These 
neurobiological endophenotypes – especially those derived from in-vivo human 
neuroimaging measures (Figure 1) – allow an investigator to probe the brain at 
the systems level to give a quantitative functional readout of the impact of a 
genetic variant on brain structure, function, neurochemistry or metabolism. This 
strategy both enhances the ability to detect genetic effects and affords a means 
of discovering plausible neurobiological risk mechanisms.  
 
 
Addiction as a Disease of Reward and Motivation 
In general, when attempting to identify etiopathophysiological pathways 
through which heritable factors might exert their effects on susceptibility for a 
given disorder, it is instructive to consider the core cognitive and behavioral 
domains that are disrupted in that disorder8. Addiction is fundamentally a disease 
Figure 1. Endophenotypes can aid in the characterization of genetic 
pathomechanims for psychiatric illness 
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of reward and motivation, and it is commonly accepted that addiction develops 
through the arrogation of evolutionarily conserved neural systems for processing 
survival-critical natural rewards  (e.g. palatable food, sex) by drugs of abuse 10-14. 
This singular fact raises the intriguing possibility that genetic risk factors may 
shape susceptibility by altering the functional properties of brain reward circuitry. 
Therefore, endophenotypes related to reward and motivation make especially 
appealing targets for identifying potential genetic risk factors and for elucidating 
the neurobiological mechanisms through which they convey liability for addiction. 
In particular, the strong link between reward, motivation, and the mesolimbic 
dopamine system15-18 implies that brain imaging endophenotypes related to 
mesolimbic dopamine function can be used to further our understanding of the 
neurobiological mechanisms of genetic risk.    
 
Addiction, Reward, and Nucleus Accumbens Dopamine 
Initial interest in DA as a neurochemical substrate for addiction developed 
from work which demonstrated that all drugs of abuse increase synaptic DA in 
the nucleus accumbens  (NAcc)19; showed that animals will work for the 
opportunity to self-administer DA potentiating drugs20-22; and appeared to 
suggest that such drugs reinforce instrumental behavior only to the extent that 
they elevate DA17. These and related findings led Wise to develop the hedonia 
hypothesis of DA, which held that “dopamine junctions represent a synaptic way 
station … where sensory inputs are translated into the hedonic messages we 
experience as pleasure23.” This hypothesis is the conceptual foundation for many 
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of the dominant neurobiological theories of drug addiction  (e.g. the reward 
allostasis model of Koob and LeMoal 12), which share the view that addiction is a 
disorder of meso-accumbens DA “pleasure” systems. Wise’s formulation of 
reward neurochemistry was premised on the assumption that the hedonic and 
motivational values of a stimulus are so inextricably linked as to be 
indistinguishable. However, more recent work suggests a neurobiological 
dissociation between these two facets of reward, and this separation has 
significant implications for how best to study addiction neurobiology in humans.  
 
Specificity of NAcc DA for Reward “Wanting” 
Berridge and Robinson were among the first to argue for a clear 
differentiation of hedonics and motivation in reward processing, which they term 
‘liking’ and ‘wanting,’ respectively24. ‘Liking’ refers to the hedonic impact of a 
stimulus – the positively valenced sensory experience that immediately follows 
reward receipt. By contrast, ‘wanting’ or ‘incentive salience’ refers to the 
motivational value of that reward – that is, its ability to drive goal-directed 
behavior. Neurobiological discrimination of “liking” and “wanting” processes arose 
from the finding that experimentally manipulating striatal DA levels appears to 
have a dissociable impact on behavioral measures of each.  Namely, using 
experimental measures that permit an empirical parsing of hedonic and 
motivational responses to rewards, Berridge and Robinsons have shown that 
altering mesolimbic DA signaling has a specific and profound effect on reward 
‘wanting,’ while reward ‘liking’ is unaltered by such changes 25. For example, 6-
 6 
hydroxy-dopamine  (6-OHDA) lesions of ascending DA-ergic projections have no 
effect on hedonic responses to sucrose, despite almost completely depleting DA 
levels in NAcc and dorsal striatum26, 27. In addition, D2R blockade does not alter 
‘liking’ responses  (to sucrose) or ‘disliking’ responses  (to quinine)28. Similarly, 
neither systemic administration of amphetamine29, amphetamine microinjections 
into NAcc30, or electrical stimulation of the medial forebrain bundle31 affect liking 
reactions to sucrose reward, although all three of these manipulations 
significantly potentiate manifestations of reward ‘wanting,’ such as food seeking 
and ingestive behaviors. Notably, genetically hyperdopaminergic and 
hypodopaminergic mice  (DAT and TH knockouts, respectively) show striking and 
directionally consistent alterations in reward ‘wanting’ behavior  (DAT knockouts 
increased, TH knockouts decreased) in the absence of corresponding changes in 
hedonic response32-36. On the whole, these data strongly and selectively 
implicate NAcc DA in energizing motivated, instrumental behavior to obtain 
rewards.  
 
Relevance of NAcc DA-mediated Reward Wanting for Addiction 
Based on the findings outlined above, Berridge and Robinson have 
argued that mesolimbic DA mediates the dynamic attribution of “incentive 
salience.” This value, when ascribed to a reinforcing stimulus, “transforms mere 
sensory information about rewards and their cues … into attractive, desired, 
riveting incentives … to make [them] a ‘wanted’ target of motivation.25” Incentive 
salience “tags” a stimulus as a target for goal-directed behavior and ensures that 
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an organism will prioritize resources towards obtaining that stimulus over others. 
Noting that that the key neurobiological nexus for the actions of drugs of abuse – 
meso-accumbens DA circuitry – is critically involved in ascribing incentive 
salience to environmental stimuli, Berridge and Robinson have hypothesized that 
drug addiction involves a dysregulation of incentive salience processing.  Their 
“Incentive Sensitization” hypothesis is based on the observation that drugs of 
abuse induce a profound and long-term hypersensitivity of this system to rewards 
and to reward-predicting cues. Repeated administration of a wide range of 
addictive drugs causes animals to become sensitized to their psychomotor 
effects  (e.g. elevated locomotor, exploratory and approach behavior). Strikingly, 
repeated exposure to psychoactive drugs also induces sensitization to their 
incentive motivational effects, even as tolerance develops to their hedonic 
effects. For example, pre-exposure to amphetamine decreases the dose and the 
time required for an animal to subsequently learn to self-administer the drug, and 
increases the amount of work they will expend to gain access to it 22, 37, 38. The 
expression of sensitization is strongly influenced by associative learning 
mechanisms, with drug-associated cues promoting excessive ‘wanting’ behavior 
long after the last drug exposure16.  The development of sensitization is 
paralleled by structural adaptations in NAcc dendritic spines, and by cellular 
alterations within the VTA and at NAcc/PFC synapses39-41. In sum, the Incentive 
Sensitization hypothesis posits that repeated exposure to an addictive drug 
sensitizes meso-accumbens circuitry for incentive motivation, leading to an 
excessive attribution of incentive salience to the drug. 
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Taken together, these preclinical findings strongly suggest that DA 
selectively mediates reward ‘wanting,’ and that excessive (i.e. sensitized) NAcc 
DA function following exposure to drugs of abuse promotes an inflexible and 
long-lasting attribution of salience to drugs and drug cues, which in turn leads to 
compulsive drug taking behavior.  While suggestive, the relevance of these 
findings for human mesolimbic function, reward experience, and addiction risk is 
not immediately clear. However, recent neuroimaging work in humans suggests 
strong cross-species parallels.  
 
Human Mesolimbic DA Function and Addiction Risk 
 
Human NAcc Activity and Reward Wanting 
Human functional neuroimaging studies recapitulate the distinction 
between wanting and liking by elucidating distinct neuroanatomical substrates for 
each, and suggest that reward-related NAcc DA function in humans is specific to 
anticipatory reward “wanting.” Several early fMRI studies demonstrated that 
monetary reward and drugs of abuse robustly activate mesolimbic and 
mesocortical DA terminal fields in humans42-46. In addition, primate 
electrophysiological work by Schultz revealed differences in the response 
patterns of NAcc and orbitofrontal neurons to the expectation and delivery of 
rewards, suggesting a neuroanatomical basis for the distinction between 
appetitive and consummatory phases of reward recognized by ethologists47. 
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 Drawing on this body of work, as well as its conceptual links to Berridge 
and Robinson’s incentive salience model of reward, Knutson and colleagues 
have shown that anticipating and receiving monetary reward activates distinct 
neural circuits. NAcc is active following the presentation of cues that signal the 
opportunity to emit an instrumental response to obtain reward, but not during the 
receipt of that reward; by contrast, medial prefrontal cortex is active following the 
attainment of monetary reward, but not during the anticipatory period preceding 
reward receipt48-51. Similar results have been observed during the anticipation 
and receipt of taste reward52. Further support for the notion that human NAcc is 
sensitive to the motivational aspects of reward, rather than reward hedonics, is 
offered by data showing that NAcc response to monetary reward is contingent on 
stimulus saliency53 and dependent on the production of an instrumental 
response54, 55.  
 
Motivation-related NAcc Activity in Addiction 
There is considerable support for the notion that dysregulated – 
specifically, sensitized – motivation-related activity in the ventral striatum (VS), a 
region that encompasses the NAcc, is linked to risk for addiction in humans. For 
example, VS activation following acute cocaine administration is positively 
correlated with subjective ratings of drug craving, but negatively correlated with 
subjective ratings of drug “high” (liking)56. In addition, enhanced VS engagement 
by drug cues has been found in substance dependent individuals, and is 
positively correlated with measures of drug craving 57-61. Notably, a recent study 
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found increased motivation-related VS activity in response to non-drug 
(monetary) reward cues in substance dependent individuals, suggesting a 
general hyper-reactivity of NAcc to motivationally salient stimuli in addiction. 
Finally, several human fMRI studies have found heightened VS activation during 
reward tasks in individuals without of history of substance abuse, but who 
possessed high levels of addiction-linked traits  (e.g. sensation-seeking, 
impulsivity, impulsive-antisociality)62-64 indicating that VS hyper-reactivity may 
constitute a trait-like factor that precedes, and contributes to risk for, the 
development of drug addiction.  
These findings imply a specific and circumscribed role for NAcc in human 
reward motivation, and suggest that VS hyper-reactivity may comprise an 
important component of addiction pathophysiology. Further, given the clear links 
between DA, VS function, reward wanting and addiction, these fMRI studies 
suggest that sensitized dopaminergic function may also be associated with risk 
for addiction. However, while some human 63, 65 and preclinical 66 research 
support the notion that the VS fMRI reward signal is driven by DA signaling, fMRI 
cannot provide compelling information about the neurochemical alterations that 
may lead to changes in measured MR signal. Radioligand PET studies – 
particularly in combination with DAergic drugs – provide an essential confirmation 
of a role for human VS DA in reward “wanting” and its putative dysregulation in 
addiction.  
 
Dopaminergic Mechanisms for Addiction-related NAcc Dysregulation 
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A series of radioligand PET studies provide a critical complement to the 
fMRI work outlined above by demonstrating that hyper-reactive DA signaling 
within the NAcc is associated with excessive reward wanting and risk for drug 
abuse.  First, Leyton and colleagues found that the magnitude of amphetamine-
induced increases in VS DA release is strongly positively correlated with changes 
in self-reported ‘drug wanting’ and with individual differences in “novelty seeking” 
trait scores 67, which have been found to be elevated in substance abusers68. 
Boileau and colleagues extended this work by demonstrating long lasting 
stimulant-induced sensitization of VS DA release in humans. Remarkably, the 
magnitude of sensitized response was strongly correlated with individual 
differences in novelty seeking trait scores and other self-report impulsivity 
measures that are also related to addiction risk 69. Of note, it has been shown 
that amphetamine-associated conditioned cues increase VS DA release to an 
extent that is comparable to the drug itself70, providing a parallel to fMRI data that 
implicate the VS in cue-induced craving.  
Importantly, using 18F-fallypride, we have recently found evidence that 
impulsive traits – which are heritable, stable, and strongly linked to addiction 
liability68 – are associated with exaggerated VS DA release following 
amphetamine administration. This enhancement in DA release in impulsive 
individuals appears to be driven, in part, by diminished somatodendritic 
autoreceptor control over midbrain DA neuron firing. Critically, we also showed 
that the magnitude of amphetamine-induced VS DA tracks subjective ratings of 
drug wanting, with increased DA release in highly impulsive subjects predicting 
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stronger drug wanting responses in these subjects71. Given that heightened 
subjective “wanting” responses are associated with risk for drug dependence72, 
and that trait impulsivity has itself been found to predict drug wanting in 
substance dependent individuals73, these data raise the possibility that excessive 
DA release during early stage drug use in impulsive individuals promotes and 
excessive, inflexible, and long-lasting attribution of salience to drugs and drug 
cues. On the whole, this series of PET studies are highly consistent with the 
hypothesis that risk for addiction is associated with VS dopaminergic hyper-
reactivity.  
 Taken together, the body of work described above indicates that human 
VS DA is associated with reward “wanting”, and demonstrates that individual 
differences in the sensitivity of the mesolimbic DA system are related to risk for 
addiction. Furthermore, given that genetic factors play a key role in determining 
addiction liability, these findings raise the suggestion that heritable individual 
differences in the responsiveness of mesolimbic DA circuitry to reinforcers – 
including drugs of abuse – may be a crucial factor mediating individual 
susceptibility to addiction. Accordingly, genetic variants that enhance the 
responsiveness of mesolimbic DA circuitry to reinforcers may increase addiction 
liability by causing an exaggerated attribution of incentive salience to reward 
stimuli. In this manner, genetically mediated individual differences in VS DA 
sensitivity may predispose the development of addiction following exposure to 
drugs of abuse. While intriguing, this hypothesis remains untested: to date, no 
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studies have examined the impact of addiction-linked genetic variation on 
individual differences in drug-induced VS DA release.  
 
Specific Aims 
 The purpose of the experiments described in this dissertation is to 
examine the impact of genetic variability on individual differences in ventral 
striatal DA reactivity. To that end, I employ molecular imaging with PET to assess 
the effects of polymorphic variants in three addiction-linked brain-signaling 
pathway genes on VS DA reactivity to a psychostimulant drug of abuse. A central 
goal of these experiments is to show that genetic risk factors in diverse brain 
signaling systems may converge to increase susceptibility through a final 
common neurobiological mechanism: sensitization of VS DA responses to drugs 
of abuse. 
Aim 1:  Characterize the impact of risk-linked allelic variation in DA 
signaling on psychostimulant-induced DA release.  
Individuals with heightened subjective responses to stimulant drugs are at 
increased risk for the development of future drug dependence. Therefore, genetic 
variants that predispose exaggerated stimulant responsiveness may be good 
candidate addiction risk factors. Chapter II of this dissertation tests the 
hypothesis that the effect of one such variant, located in the DA signaling 
pathway gene CSNK1E, is driven by its sensitizing influence on stimulant-
induced VS DA release.  
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Aim 2: Test for functional interactions between genetically-mediated 
differences in stress responsiveness and human DA function. 
 Stress is a prominent risk factor for both the development of compulsive 
drug use and for relapse behavior following a period of abstinence. This strong 
association implicates individual variability in the function of stress-linked 
neurobiological factors – particularly those comprising the hypothalamic-pituitary-
adrenal  (HPA) stress axis – in addiction risk. However, despite an extensive 
preclinical literature demonstrating regulation of striatal DA signaling by HPA-axis 
factors, compelling demonstration of a relationship between variation in stress 
responsiveness and striatal DA function in humans is lacking. In chapter III, I 
investigate the possibility that genetic variability in one HPA-axis gene – CRH, 
encoding the corticotropin-releasing hormone – potentiates striatal DA release, 
which may provide a translational mechanism accounting for the known 
sensitizing effects of stress and stress susceptibility on DA function and drug-
taking behavior in animals.  
Aim 3: Demonstrate regulation of human striatal DA function by energy-
regulating hormones. 
Obesity is burgeoning public health problem with prominent psychological 
and neurobiological parallels to addiction. Notably, the most well characterized 
genetic risk factor for obesity – the energy-regulating hormone leptin – is known 
to modulate mesolimbic DA system function in rodents. However, it is unknown 
whether individual differences in energy-regulating hormone signaling might also 
play a role in regulating human mesolimbic DA system reactivity. Chapter IV of 
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this dissertation provides genetic evidence for leptin-DA interactions in the 
human striatum; such interactions may provide a plausible mechanism explaining 
the psychobiological parallels between obesity and addiction.  
At the conclusion of this dissertation, I will detail the contributions of these 
experiments to our understanding of the neurogenetic architecture of addiction. 
Further, I will outline a proposal for bootstrapping this new understanding to 
devise novel approaches to gene finding in addiction. For example, while a 
candidate gene approach based on the known pathobiology of addiction has 
been critical in identifying risk-linked genetic markers, there are likely many as-
yet-undiscovered risk factors lurking in the genome. Exploratory, data-driven 
approaches such as genome-wide association studies provide one route for 
novel gene discovery, but the issues inherent to diagnosis-based genetic 
association identified above make this approach problematic. I will offer that 
genome-wide association studies using validated quantitative biological 
endophenotypes – such as stimulant-induced DA release – may provide a more 
robust method for gene finding in substance abuse.  
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CHAPTER II 
 
ALLELIC VARIATION IN THE DOPAMINE REGULATING GENE CSNK1E 
SENSITIZES STIMULANT-INDUCED STRIATAL DOPAMINE RELEASE 
 
 Drug abuse is a serious public health problem with significant costs to 
affected individuals and to society as a whole. While approximately 9% of 
Americans are estimated to meet the criteria for DSM-IV substance use 
disorders1, 2, many more people are thought to use drugs in a recreational  (non-
compulsive or dependent) fashion. Indeed, it is noteworthy that despite the fact 
that all drugs of abuse strongly affect neural systems for reward and motivation 
and are highly reinforcing, only a relatively small percentage of individuals who 
are exposed to drugs of abuse go on to develop a destructive pattern of 
compulsive drug seeking and taking that persists even in the face of significant 
adverse consequences – the hallmark of addiction4. Thus, there appear to be 
significant individual differences in susceptibility to drug addiction following drug 
exposure14. However, we do not yet have a full accounting of the specific risk 
factors that predict conversion from recreational drug use to drug addiction, and 
neurobiological correlates for even the most well characterized risk factors are 
still largely unknown5, 74. Therefore, the identification of specific predictors of 
addiction liability and the elucidation of their underlying pathophysiological 
mechanisms represents a critical scientific goal.    
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 While the risk architecture for addiction conversion (i.e. the transition from 
early-stage, recreational drug use to compulsive drug-taking) is complex and 
multiply determined, one factor that has emerged as potentially important is an 
individual’s subjective responses during their initial or early exposure to a drug of 
abuse.  For example, subjective responses to alcohol are a strong predictor of 
alcohol use problems, such that high-risk individuals can be distinguished by the 
presence of enhanced “stimulant” effects and diminished sedative effects of the 
drug75. Similarly, Lambert and colleagues found that individuals who report 
higher subjective “wanting” responses during their initial exposure to cocaine are 
at markedly increased risk for meeting criteria for cocaine dependence72. These 
findings accord well with preclinical data indicating that individual differences in 
behavioral responses during initial exposure to a drug of abuse significantly 
predict whether or not an animal goes on to develop addiction-like behavior  (e.g. 
drug self-administration)21, 22. Of note, subjective responses to drugs of abuse 
are significantly correlated with other established trait risk factors, such as 
sensation seeking76, providing convergent evidence for the relevance of 
subjective responses in determining individual liability to addiction conversion.  
  The high heritability of addiction5, 6 implies that genetic mechanisms may 
predispose risk, and further, raises the possibility that heritable mechanisms may 
play a role in determining individual differences in subjective drug responses. 
Available evidence suggests that this is in fact the case. For example, subjective 
responses tend to track other established genetic risk factors for substance 
abuse, such as the presence of a family history of alcoholism75, 77. Furthermore, 
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several groups have reported that genetic factors account for a significant degree 
of variance in subjective responses to alcohol, tobacco, and marijuana 78-80. 
Interestingly, multivariate genetic modeling in those studies delineated a role for 
both common and drug-specific genetic factors in accounting for individual 
variance in subjective responses78. On the whole, these findings strongly suggest 
that alterations in subjective responses to drugs of abuse may be one 
psychological mechanism through which genetic susceptibility factors may exert 
their effects81-83. Such alterations – especially, the sensitization of positive effects 
– may in turn promote the transition to an addicted state.     
Consistent with the data of Haberstick and colleagues illustrating the 
importance of genetic factors generally in predisposing individual differences in 
drug responses, a number of investigators have found associations between 
specific genetic variants and aspects of subjective experience following drug 
exposure. For example, polymorphisms in the GABRA2, CNR1, OPMR1, and 
ALDH2 genes have been linked to subjective responses to alcohol 
consumption84-89, and alleles in CSNK1E, SLC6A4, SLC6A2, SLC6A3 and FAAH 
have been shown to predict subjective responses to stimulant administration90-96. 
Of these stimulant-associated polymorphic variants CSNK1E is a particularly 
intriguing candidate, with especially strong translational evidence supporting a 
causal role for this gene in determining responses to drugs of abuse.       
 CSNK1E encodes the epsilon isoform of casein kinase 1 (CK1E), a 
serine/threonine kinase that is an important regulator of the striatally-enriched DA 
signaling protein DARPP-32  (dopamine and cAMP-regulated phosphoprotein of 
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molecular weight 32 kDa)97. By way of review, DARPP-32 is highly expressed in 
midbrain dopamine neuron terminal field regions, with peak expression in the 
medium spiny neurons  (MSNs) of the caudate, putamen and nucleus 
accumbens, and is known to play an important role in orchestrating second and 
third messenger signaling cascades within MSNs following exposure to all known 
classes of abusable drugs98.  In the context of the present discussion, it is 
notable that DARPP-32 has also been found to mediate both the locomotor 
activating and reinforcing effects of amphetamine99, 100. The involvement of 
DARPP-32 in determining psychostimulant responsiveness is likely a function of 
the role that this molecule plays in amplifying the effects of DA D1 receptor 
stimulation on protein kinase A (PKA) signaling within MSNs101.  
Amphetamine administration leads to higher levels of synaptic DA, which 
results in enhanced stimulation of post-synaptic D1 receptors on MSNs. D1 
stimulation, in turn, activates PKA, which phosphorylates DARPP-32 at Thr-34, 
dramatically potentiating its affinity as an inhibitor of protein phosphatase I (PP-
1)102.  PP-1 inhibition causes enhanced phosphorylation at multiple target 
proteins, including receptors for excitatory amino acids in the neuronal plasma 
membrane and nuclear-localized cAMP response element binding protein  
(CREB), a crucial regulator of gene expression (Figure 1). CK1e positively 
regulates the DARPP-32 mediated inhibition of PP-1 by phorphorylating DARPP-
32 at Ser-137; this, in turn, decreases the rate of Thr-34 dephosphorylation by 
protein phosphatase-2B (PP2B or calcineurin) and, by so doing, increases the 
overall level of phosphorylation of DARPP-32 by PKA at Thr-34. Thus, the net 
 20 
effect of CK1E is to increase the phosphorylation state of the Thr-34 residue of 
DARPP-32, thereby magnifying the impact of drug-induced stimulation of post-
synaptic D1 receptors in striatal MSNs103-105. Overall, these data hint that CK1E, 
by acting to modify the phosophorylation state of DARPP-32, may impact 
stimulant responsiveness.  
 
Specific evidence for the involvement of CK1E in psychostimulant 
responsiveness can be gleaned from a series of translational studies. First, using 
a model of cocaine sensitization in Drosophila, Andretic and colleagues found 
blunted responses to acute cocaine and abolished sensitization in flies carrying a 
mutated form of the Drosophila protein doubletime, which has significant 
homology to the epsilon isoform of human CK1E106.  Next, using a behavioral 
quantitative trait locus (bQTL) approach, Palmer and colleagues investigated the 
Figure 1. CK1e regulates phosphorylation of DARPP-32 at Ser137, 
potentiating the PKA-mediated phosphorylation at Thr34 required for 
inhibition of PP-1 
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linkage between genomic variability and individual differences in psychostimulant 
responsiveness – specifically, locomotor activation following methamphetamine 
administration – in mice that were bred selectively to highlight such differences. 
This identified a responsiveness-linked region on chromosome 15 that 
encompassed the murine CSNK1E gene. Subsquent microarray-based QTL 
analysis using nucleus accumbens tissue revealed an expression QTL for 
stimulant responsiveness that also mapped to the CSNK1E gene region, 
suggesting that variability in the behavioral phenotype might be caused by 
genetic factors that drive changes in accumbens CK1E expression107. Further 
supporting the hypothesis that accumbens CK1E activity is a critical regulator of 
responsiveness through its facilitatory actions on DARPP-32 Thr-34 
phosphorylation, a recent study showed that selective pharmacological inhibition 
of accumbens CK1E activity dramatically attenuated locomotor responses to 
methamphetamine, while at the same time abolishing stimulant-induced 
phosphorylation of DARPP-32108.  
Extending these findings to humans, Veenstra-VanderWeele and 
coworkers examined associations between SNPs in the human CSNK1E gene 
and subjective responses to an oral dose of D-amphetamine (placebo, 10mg and 
20mg; administered in a double-blind, randomized, three-session crossover 
design). They found one SNP downstream from the 3’ untranslated region  (UTR) 
of the CSNK1E gene  (rs135745) that was associated with two measures of 
subjective drug response: the Drug Effects Questionnaire  (DEQ) “Feel Drug” 
scale, and the ARCI “euphoria” scale. Individuals carrying one or more C allele at 
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this locus had significantly greater subjective responses as measured by both 
scales relative to G allele homozygotes 95. Taken together, these translational 
findings indicate that CK1E is a critical determinant of stimulant responsiveness – 
likely through its modulatory effects on DARPP-32 phosphorylation – and that 
polymorphic variation at the human gene encoding the CK1E epsilon isoform  
(CSNK1E) predicts individual differences in human subjective responses to 
stimulant administration.  Thus, CSNK1E represents a compelling candidate 
gene for addiction conversion. However, despite the suggestive linkages 
described above, the specific neurobiological mechanisms through which 
variation in CSNK1E exerts its effect on subjective responses and  (putatively) 
addiction risk remain unknown.  
To gain purchase on the systems-level biological effects that may 
underpin the linkage between CSNK1E genetic variation and stimulant 
responsiveness in humans, we employed positron emission tomography  (PET) 
imaging with the high-affinity D2/D3 ligand [18F]fallypride, in concert with an 
amphetamine challenge. This approach provides an in-vivo measure of 
stimulant-induced DA release, which we compared across CSNK1E rs135745 
genotypes in our sample of healthy community volunteers. Given the robust 
linkage – preclinically and in humans – between ventral striatal  (VS) DA levels 
and drug wanting, the selective associations between VS CK1E and drug 
responsiveness, and the impact of CSNK1E rs135745 genotype on positive 
subjective responses to amphetamine, we hypothesized that CSNK1E rs135745 
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C allele carriers would release significantly more DA within VS in response to 
amphetamine administration.    
 
Methods 
Participants 
We studied 59 individuals  (29 males; age range = 18-33, mean = 23; 48 
Caucasian, 5 African-American, 3 Asian, and 1 individual of mixed Caucasian 
descent; Table 1) using a dual-scan placebo-controlled paradigm with 
[18F]fallypride PET and d-Amphetamine  (AMPH).  All participants were 
medically and psychiatrically healthy adults, age 18 to 35, with estimated IQ 
greater than 80.  Subjects were excluded if they had any history of substance 
abuse, current tobacco use, alcohol intake greater than 8 ounces of whiskey or 
equivalent per week, use of psychostimulants  (excluding caffeine) more than 
twice in the subject’s lifetime or at all in past 6 months, any psychotropic 
medication for the past 6 months other than occasional use of benzodiazepines 
for sleep, history of psychiatric illness, significant medical condition, any condition 
which would interfere with MRI or PET studies  (e.g., extreme obesity, 
claustrophobia, cochlear implant, metal fragments in eyes, cardiac pacemaker, 
neural stimulator, and metallic body inclusions or other metal implanted in the 
body which may interfere with MRI scanning, pregnancy, or anemia).  Female 
participants were studied during the early follicular phase of their menstrual 
cycle. 
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Following initial screening, subjects were given an interview of their 
medical history and a structured psychiatric interview  (SCID-NP;109). In addition 
to the regular questions in the non-alcohol substance dependence section of the 
SCID-NP, subjects were asked to indicate the number of times that they have 
taken any drug that they reported having tried, and asked to indicate any usage 
within the last 2 months. Any illicit drug use in the last 2 months was grounds for 
exclusion, even in subjects who did not otherwise meet criteria for substance 
abuse. Urine drug screens were performed to test for the presence of 
amphetamines, cocaine, marijuana, PCP, and opiates, benzodiazepines, and 
barbiturates.  
 
 
Genotyping 
Saliva was collected from each subject using DNA Genotek Oragene-250 
collection kits. Genomic DNA was extracted per manufacturer’s protocols and 
banked at the Vanderbilt University Center for Human Genetics Research DNA 
Resources Core. Genotyping for rs135745 was conducted by Vanderbilt DNA 
Resources Core through the use of the Sequenom massARRAY genotyping 
platform, based on a single-base primer extension reaction coupled with mass 
Table 1. Demographic information for CSNK1E PET Sample  
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spectrometry. Genotyping for the participants reported in this study was 
performed in two separate genotyping runs, as part of a larger batch of 
genotyping that included DNA collected as part of an unrelated study. The 
genotyping success rate for this marker was high (96.6%).  Allele frequencies 
were as follows: C/C = 13, C/G = 27, G/G = 17, and did not deviate from Hardy-
Weinberg Equilibrium  (p = 0.72).  Genotype was not significantly associated with 
age  (F = 0.36, p = 0.71), but we did find trends for imbalances in genotype 
distribution across sex  (X2 = 4.83, p = 0.09) and self-reported ethnicity  (X2 = 
10.38, p = 0.11) (see Table 1). Therefore, we controlled for the potentially 
confounding effects of this imbalance in subsequent between-groups genetic 
analyses.  
 
PET 
Image Acquisition and Analysis 
  All PET images were acquired using [18F]fallypride.  ( (S)-N-[ (1-allyl-2-
pyrrolidinyl)methyl]-5- (3[18F]fluoropropyl)-2,3-dimethoxybenzamide), a 
substituted benzamide with very high affinity for D2/D3 receptors110. Unlike other 
D2/D3 ligands, [18F]fallypride allows stable estimates of D2-like binding in both 
striatal and extrastriatal regions111. Our current resolution  (see below) allows 
visualization of [18F]fallypride binding potential in the substantia nigra  
(SN)/ventral tegmental area  (VTA), [for a discussion of the spatial resolution 
requirements for detecting activity in the SN see 112]. However, this resolution 
does not permit us to cleanly distinguish between different DA cell populations, 
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preventing a clear parcellation of the VTA from the neighboring SN, which 
possesses higher levels of D2-like receptors. Previous studies have 
demonstrated good intersubject and intratest-retest reliability for measurement of 
[18F]fallypride binding potential for the DA midbrain at the current resolution113-115. 
[18F]fallypride binds with high affinity to both presynaptic  (“D2-short”) and 
postsynaptic  (“D2-long”) D2-like receptors116. However, because DA receptor 
expression in the midbrain is dominated by the D2-short receptor isoform 117 
variance in [18F]fallypride BPND within the midbrain is presumed to be driven by 
individual differences in these D2-short autoreceptors. 
In addition, [18F]fallypride has been found to be sensitive to endogenous 
DA release 114, 118, particularly in the striatum, making it an ideal ligand for use in 
conjunction with a dual scan strategy that allows assessment of both baseline 
receptor availability and individual differences in induced DA release. Baseline 
binding of [18F]fallypride is also influenced by endogenous DA levels, and thus 
provides a metric of receptor availability, rather than absolute receptor density.  
However, receptor availability has proven a highly useful measure in quantifying 
individual differences in DA functioning, and indeed in some ways may be a more 
relevant variable than receptor density examined in isolation  (as only available 
receptors can be engaged at a given point in time).                                                
Protocols for PET image acquisition and analysis were derived from a 
larger ongoing study and have been previously published 114, 115. Subjects 
received two PET scans using [18F]fallypride. The first scan was a baseline 
placebo scan; the second scan was performed while the subject received an 
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amphetamine  (d-AMPH) challenge. We used a single-blind drug administration 
regimen for the majority of participants  (n = 43); however, we also included in 
our analyses 14 subjects who participated in the study during a pilot phase, and 
who were not blind to drug. We do not observe an imbalance of genotypes 
between blind and non-blind subjects  (Pearson X2 = 1.6, p = 0.45); nevertheless, 
blinded status was included as a nuisance covariate in all analyses where it was 
appropriate to do so  (i.e. in analyses that included non-blind participants). PET 
imaging was performed on a GE Discovery LS scanner located at Vanderbilt 
University Medical Center that was upgraded to a Discovery STE system during 
the course of the study. All subjects received their baseline and d-AMPH scans 
on the same scanner. To ensure the validity of combining data across scanners, 
we performed a voxel-wise analysis comparing DA release between the two 
scanners.  No clusters survived whole brain correction at t = 2.5  (lowest cluster-
level p-value >.90).  Moreover, no differences were observed in our anatomical 
region of interest, the ventral striatum. (left and right VS; both p-values > 0.45). 
24 participants were scanned on scanner 1, and 33 participants were scanned on 
scanner 2. We did observe a trend for an imbalance of genotypes between the 
two scanners  (pearson Χ2 = 5.58, p = 0.06; Table 1). We therefore included 
scanner  (i.e. scanner 1 vs. scanner 2) as a nuisance covariate in all of our 
regression analyses. Following reconstruction both scanners had similar in plane 
and throughplane resolution.  [18F]fallypride was produced in the radiochemistry 
laboratory attached to the PET unit, following synthesis and quality control 
procedures described in US Food and Drug Administration IND 47,245.  Scans 
 28 
were timed to start 3 hours after 0.43mg/kg oral d-AMPH administration, which 
was timed to coincide with the period of peak plasma d-AMPH. 3-D emission 
acquisitions scans were performed following a 5.0 mCi slow bolus injection of 
[18F]fallypride  (specific activity greater than 3000 Ci/mmol). Serial scans were 
started simultaneously with the bolus injection of [18F]fallypride and were 
obtained for approximately 3.5 hours, with two 15-minute breaks for subject 
comfort. CT transmission scans were collected for attenuation correction prior to 
each of the three emission scans.  
 
Binding Potential Maps 
Each subject’s serial PET scans were first corrected for motion across 
scanning periods and then co-registered to the subject’s structural T1-weighted 
MRI image.  To determine the success of the coregistration in the midbrain, in a 
prior study of 34 subjects115 we manually labeled several landmarks around the 
midbrain, including the posterior edge of the right and left inferior colliculus, the 
anterior-most point of the right and left cerebral peduncle and the interpeduncular 
fossa at z = 10, and the inferiormost point of the supramammillary commissure. 
Of these 34 subjects, all but one showed excellent midbrain coregistration, with 
no tag varying by 2mm in any direction from the mean coordinate of the tag  
(across these 33 subjects, the mean distance in any direction from the average 
tag was 1mm for every tag examined). Given the spatial resolution of the PET 
images, this degree of misregistration is at the subvoxel level, and would have 
negligible impact on the results. 
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Regional D2/D3 binding potential  (nondisplaceable; BPND) was calculated 
on a voxelwise basis using the full reference region method119, with cerebellum 
chosen as the reference region because of its relative lack of D2/D3 receptors120. 
Voxelwise kinetic modeling was executed using Interactive Data Language. Prior 
studies in our lab indicate that the reference region method produces binding 
potential estimates that are in close agreement with estimates derived from 
Logan plots 121 using a metabolite corrected plasma input function. Because 
[18F]fallypride binding values exhibit significant variability across different regions  
(e.g., striatum vs. prefrontal cortex; PFC), we used variance estimates at the 
voxelwise level rather than the pooled variance used in typical parametric 
analyses 122. Individual images of percent-change in [18F]fallypride binding from 
placebo to amphetamine  (representing percent-change in DA release) were 
created by subtracting each subject’s amphetamine scan from their placebo scan 
and dividing the resulting imaging by the placebo scan, using the “imcalc” image 
math routine in SPM5. 
 
Region of Interest Analyses 
 Based on the large body of preclinical and human research linking 
psychostimulant responsiveness to ventral striatal dopamine 24, 67, 71, 123, 124, we 
limited our analysis of the effects of CSNK1E genetic variation on stimulant-
induced DA release to the ventral striatum. To that end, we constructed an 
anatomical VS region of interest (ROI) by manually editing the striatum ROI 
derived from the LONI Probabilistic Brain Atlas 40  (LPBA40;125) according to the 
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criteria outlined in Mawlawi et al. (2001)126, 127  (Figure 1). Percent-change values 
were averaged across all voxels within left and right VS ROIs to create a single 
percent-change value for each individual’s left and right VS mask.   
 
 
 
 
 
Measurement of Subjective Response to AMPH 
To measure subjective responses to amphetamine, we administered the 
Drug Effects Questionnaire  (DEQ) at 60-minute intervals following the 
administration of drug and placebo. The DEQ consists of four questions: whether 
the subject feels the drug, whether the subject likes the drug, whether the subject 
feels high, and whether the subject wants more of the drug. Subjects indicated 
their response on a labeled magnitude scale 128 from 0-100, with 0 indicating “Not 
Figure 2. Striatal Regions of Interest (ROIs). ROIs rendered on a T1-
weighted reference image, coronal slice at Y = 11 (MNI space). ROIs 
defined by anatomical criteria of Mawlawi et al (2001). Only pre-
commisural ROIs shown.  
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At All” and 100 indicating “Most Imaginable.” Participants made these ratings 5 
times over the course of a session, approximately every 60 minutes after the 
administration of drug or placebo. We used the peak rating within the AMPH day 
timecourse for our genotype effect analyses and our DA release correlation 
analyses.  
 
Statistical analysis 
Statistical analyses using were performed using SPSS 17.0 for the 
Macintosh. To test for genotype effects on VS DA release, we used a linear 
regression model with rs135745 genotype (dummy coded as 1 = C/C, 2 = C/G, 3 
= G/G) as a predictor of left and right % change in DA release  (separate models 
for left and right VS). For each ROI, we used the mean percent-change in DA 
release value averaged across all voxels within that ROI  (described above). PET 
scanner, ethnicity, and sex were included in the regression model as nuisance 
covariates. In follow-up control analyses, we added blinding status and VS BPND  
as additional nuisance covariates. Two-tailed tests were used, with alpha = 0.05.  
Whole-brain genotype effect analyses were performed using SPM5 
running on Matlab R2007b for the Macintosh. We used a linear regression model 
with rs135745 genotype  (dummy coded as 1 = C/C, 2 = C/G, 3 = G/G) as a 
predictor of voxelwise DA release (i.e. we used voxelwise images of percent-
change in DA release following AMPH administration, as described above). 
Scanner, ethnicity, blinding status and sex were included as nuisance covariates. 
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To test for genotype effects, we used an uncorrected exploratory threshold of p < 
0.005, coupled with a cluster extent threshold of 20 voxels.  
To test for an association between CSNK1E genotype and subjective 
responses to AMPH, we performed a multivariate general linear model (GLM) 
analysis of covariance (MANCOVA) with each of the four DEQ scales as 
dependent measures, CSNK1E rs135745 genotype as a fixed factor, and sex 
and ethnicity as covariates. Two-tailed tests were performed, with alpha = 0.05. 
We used the peak responses on the amphetamine day for our genotype 
comparisons and for the correlations with amphetamine-induced VS DA release.  
 
Results 
 
Descriptive and inferential statistics for VS BPND and AMPH-induced DA 
release 
Across the entire sample, mean (standard deviation) baseline BPND values 
in the left and right VS ROIs were 22.07 (3.77) and 21.05  (3.83). Mean post-
AMPH BPND values in the left and right VS ROIs were 20.83 (3.83) and 19.99  
(3.73). Repeated-Measures Analysis of Variance  (ANOVA) confirmed a 
significant reduction in BPND in both left  (F1,56 = 40.52, p = 0.000000038) and 
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right VS  (F1,56 = 33.46, p = 0.000000340) following AMPH administration  (Fig 2). 
 
 
 
CSNK1E genotype effect on VS DA release 
To test for an association between CSNK1E rs135745 genotype and 
AMPH-induced DA release, we regressed rs135745 genotype against mean 
percent-change AMPH-induced DA release values calculated from left and right 
VS ROIs. This analysis revealed that rs135745 genotype was a significant 
predictor of AMPH-induced DA release in both left  (β = -0.33, p = 0.02) and right  
(β = -0.29, p = 0.04) VS  (Figure 3). These effects remained significant  (p < 0.05) 
when blinding status was included in the model. CSNK1E genotype was not 
Figure 3. Amphetamine significantly reduced [18F]fallypride binding 
potential in ventral striatum. Binding potential (BPND) values on 
placebo (PLAC) and amphetamine (AMPH) depicted for left and 
right ventral striatum for 59 participants with dual-scan PET data. 
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significantly associated with baseline D2/D3 binding within VS (left or right; both 
p-values > 0.1), and CSNK1E remained a significant predictor of VS DA release 
even after controlling for individual variation in VS D2/D3 BPND  (left VS, p = 0.03; 
right VS, p = 0.07). 
 
 
 
 
 
Whole brain exploratory analysis 
To examine unhypothesized effects of CSNK1E rs135745 genotype 
outside of the striatum, we performed a whole-brain regression analysis in SPM5. 
At a liberal (uncorrected) exploratory statistical threshold, we did not observe any 
extrastriatal voxels in which AMPH-induced DA release was significantly 
predicted by genotype. Similarly, we did not observe any effects of CSNK1E 
genotype on baseline D2/D3 levels in any brain region at our exploratory 
threshold. 
 
 
 
Figure 4. Effects of CSNK1E rs135745 genotype on AMPH-induced 
DA Release in left (A) and right (B) ventral striatum. Error bars 
indicate ± 1 standard error of the mean, 
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CSNK1E Genotype Effect on Subjective Responses to AMPH 
Given the findings of Veentra-Vanderweele and colleagues, we sought to 
examine the relationship between CSNK1E rs135745 genotype and subjective 
responses to AMPH. DEQ data were available for 43 participants  (CC = 10, CG 
= 21, GG = 11). Repeated-Measures ANOVA confirmed that AMPH increased 
scores on each of the four DEQ scales  (“Want”, “Like”, “Feel” and “High”; all p’s 
< 0.01). However, we did not find a significant association between genotype and 
subjective response in this small sample any of the 4 scales  (p’s >0.1).  
 
VS DA Release Predicts Subjective Responses to AMPH 
Although we did not find a significant relationship between CSNK1E 
rs135745 genotype and subjective responses to AMPH, CSNK1 may exert an 
indirect effect on subjective responsiveness by influencing AMPH-induced DA 
release. That is, while no direct relationship was observed in the current sample, 
finding a correlation between AMPH-induced DA release and subjective 
responses to AMPH would support the idea that the effect of genetic variation in 
CSNK1E on AMPH responsiveness found previously by Veenstra-VanderWeele 
and colleagues 95 is mediated by an effect of CSNK1E rs135745 on stimulant-
induced DA release. To test this notion, we performed a partial correlation  
(controlling for sex and PET scanner; subjective response data was not obtained 
for non-blinded participants) between VS AMPH-induced DA release and each of 
the four DEQ scales. We found a significant correlation between bilateral VS DA 
release and DEQ Wanting (Left VS: r = 0.37, p = 0.018; Right NAcc: r = 0.41, p = 
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0.007), consistent with the idea that the magnitude of DA release in VS in 
response to AMPH is directly related to the magnitude of an individual’s 
subjective craving response to AMPH. Correlations between the three other 
scales  (Like, Feel, and High) were not significant  (p’s > 0.1).     
 
Discussion 
 Here, we present data indicating that a polymorphic variant in the 
CSNK1E gene – a compelling candidate gene for variation in stimulant 
responsiveness – is associated with the magnitude of stimulant-induced DA 
release in the human ventral striatum. Each rs135745 C allele was associated 
with a step-wise increase in ventral striatal DA release, which was in turn 
associated with subjective craving responses to AMPH. The present data 
suggest a neurobiological mechanism – striatal DA hyperreactivity to AMPH – 
that may account for a prior association with the same allele to positive 
subjective responses to AMPH95. Thus, our findings support the view that 
CSNK1E genetic variability contributes to the heritability of stimulant 
responsiveness. Furthermore, insofar as individual differences in stimulant 
response predict risk for stimulant abuse, these data suggest that CSNK1E 
warrants more extensive investigation as a susceptibility gene for addiction. 
 The molecular biology of CK1E alone makes it an intriguing candidate for 
investigation as an addiction liability factor.  As detailed previously, CK1E is richly 
expressed in striatum where it acts as an important regulator of DARPP-32 
activity105. In particular, CK1E stabilizes the D1 activation-mediated 
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phosphorylation of DARPP-32 at Thr-34, thereby potentiating its inhibition of 
PP1. Stimulant-induced phosphorylation at Thr-34 appears to be an essential 
mechanism underpinning DARPP-32’s role in mediating locomotor responses to 
stimulant administration. Therefore, CK1E is well situated to modify the impact of 
stimulant drugs on post-synaptic DA signaling by potentiating DARPP-32’s 
inhibition of PP-1, which in turn impacts a range of molecular targets, including 
fast-acting neurotransmitter receptors and voltage-gated ion channels103-105. The 
importance of CK1E for modulating stimulant regulation of this pathway is 
highlighted by recent evidence that CK1E is necessary for stimulant 
responsiveness: pharmacological inhibition of CK1E significantly attenuates 
stimulant-induced locomotion, and does so by downregulating the 
phosphorylation state of the DARPP-32 Thr-34 residue following stimulant 
administration108.   
 In addition to its effects on DA signaling through DARPP-32, CK1E is a 
potent regulator of circadian gene pathways. Given that circadian clock proteins 
such as Clock, Period2 (Per1) and Period2 (Per2) are increasingly recognized to 
play an important role in reward and motivation129-133, interactions between CK1E 
and these molecules represent another potential mechanism through which 
allelic variability in CSNK1E might impact striatal dopaminergic function and drug 
responses. In considering how individual differences in CK1E signaling might 
affect this pathway to sensitize stimulant responsiveness, a wealth of data 
implicate Per2 as a likely target.  Per2 is known to play an important role in the 
locomotor stimulatory and reinforcing effects of stimulant drugs:  in particular, 
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Per2 mutants demonstrate dramatically enhanced cocaine sensitization and 
conditioned place preference compared to wild-type animals134, and Per2 gene 
expression is significantly upregulated in the striatum following cocaine self-
administration135. Moreover, Hampp and colleagues have reported that Per2 
mutant mice show significantly higher levels of DA release compared with wild-
type animals, an effect that is likely due to downregulated MAOA expression 
within VTA and ventral striatum in Per2 mutants136. This finding is all the more 
intriguing given evidence that Per2 mutants show enhanced alcohol 
consumption, and in light of the fact that genetic variability in the human PER2 
gene is linked to alcohol intake137. Critically, CK1E plays an essential role in the 
stabilization and localization of Per2 protein. CK1E downregulates Per2 activity 
by targeting it via phosphorylation for proteosomal degradation, and this residue-
specific phosphorylation is a critical determinant of Per2 half-life138, 139. Thus, 
CK1E is in a position to have a significant and broad impact on Per2 function, 
providing one potential route for explaining how genetic variation in CK1E could 
affect mesolimbic DA reactivity.  
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 Though the precise functional effect of the rs135745 SNP on gene 
expression or post-translational modification is not known, it is nevertheless 
tempting to hypothesize a potential mechanism for CK1E’s involvement in VS DA 
responses based on several known factors. First, rs135745 is located in the 3’ 
UTR of the CSNK1E gene (Figure 4), raising the possibility that variation at this 
locus disrupts an miRNA target site; such a disruption would interfere with 
miRNA-associated translational repression of CK1E protein, leading to higher 
CK1E levels.  
Figure 5. CK1e phosphorylation is necessary for the proteasomal 
degradation of PER2. Image obtained from biocarta.com. 
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This is particularly of interest in light of a prior QTL study in mice showing that 
heightened ventral striatal CK1E mRNA expression was associated with 
exaggerated behavioral responses to amphetamine107. Higher CSNK1E 
expression could, in turn, lead to hyperphosphorylation and enhanced 
proteasomal degradation of PER2. As PER2 mutants show reduced MAOA 
expression and hyperdopaminergia in mesolimbic circuitry, CSNK1E-mediated 
acceleration of PER2 degradation could indirectly affect the amount of 
presynaptic DA available for release. Additionally, PER2 is under direct 
regulatory control by PP1: reducing PP1-mediated dephosphorylation – as would 
occur if higher levels of CSNK1E potentiated DARPP-32 inhibition of PP1 — 
accelerates PER2 degradation. Though speculative, allelic variation in the 3’ 
Figure 6. Exonic structure and genomic context of CSNK1E gene on 
chr.22. Depicts linkage disequilibrium structure of the region 
surrounding CSNK1E gene, as well as the position of HapMap SNPs 
(Release 3, Version 2). rs135745 highlighted with red box and genomic 
position indicated with blue arrow.  
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region of CSNK1E could enhance CSNK1E expression; this enhanced CSNK1E 
expression could, in turn, downregulate PER2, leading to reduced MAOA 
expression and mesolimbic DA hypereactivity.   
 This study has several important limitations to consider. First, as 
mentioned, the functional effect of variation at the rs135745 locus is not currently 
known. More study of this variant is required to understand if it is functional in its 
own right or is, rather, in linkage disequilibrium with the true causative variant. 
Even if the effects that we observe on stimulant-induced DA release, and which 
others have observed on subjective stimulant responses, are in fact due to the 
rs135745 SNP, this single variant in isolation is only going to account for a small 
proportion of the variance in a complex and multiply determined trait such as 
drug responsiveness. To fully characterize the genetic architecture of this trait – 
that is, to more completely account for the known heritability of individual 
differences in subjective drug responses – much more work is necessary. Future 
investigations would do well to focus on a genome-wide survey of potential 
candidate SNPs using stimulant responsiveness as a quantitative trait. In 
addition, exome sequencing of gene networks – such as the CSNK1E 
interactome – that might be linked to this trait may also bear significant fruit. 
Furthermore, although one might predict on the basis of available data that 
CSNK1E might be involved in risk for substance abuse (particularly, in risk for 
stimulant abuse), it remains unclear from research to date whether this is in fact 
the case. There is only one reported examination of association between 
CSNK1E and stimulant  (methamphetamine) dependence, and this was negative 
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for association with rs135745. However, that study utilized a Japanese sample, 
and allele frequencies for rs135745 are dramatically different between European 
and Japanese  (HapMap Release 28, August 2010; dbSNP 126)140. Interestingly, 
one study did find a nominally significant CSNK1E haplotype association to 
heroin addiction, though the SNP reported here (rs135745) was not tested for 
association in that study. Finally, our sample was ethnically heterogenous, 
raising the possibility that our observed associations are due to population 
admixture. The decision to include non-caucasian participants was motivated by 
a desire to obtain as large a sample size as possible, and our study recruitment 
was blind with respect to ethnicity. To address potential concerns related to 
stratification, we included self-reported ethnicity as a nuisance covariate in all of 
our general linear model analyses. Further, the impact of rs135745 on VS DA 
release remains significant even after we reanalyzed our data excluding non-
Caucasian participants (all p’s < 0.05). However, we acknowledge that we cannot 
completely rule out the possibility of spurious association due to cryptic ethnic 
stratification. The use of ancestry informative markers in future studies will 
enable us to detect population structure in our data and correct for its effects.     
  In this paper, we report that a polymorphic variant in the CSNK1E gene is 
associated the magnitude of striatal DA release in response to AMPH. As this 
same variant has been shown previously to predict euphoric subjective 
responses to AMPH, we believe that dopaminergic hyper-reactivity may account 
for this effect. Insofar as stronger subjective and striatal DA responses to drugs 
of abuse predict risk for drug dependence, these data support a role for 
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genetically-mediated individual differences in CSNK1E signaling in addiction 
liability.  
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CHAPTER III 
 
GENETIC VARIABILITY IN HPA-AXIS FUNCTION ALTERS HUMAN STRIATAL 
DOPAMINERGIC REACTIVITY 
 
 Considering both direct (e.g. treatment and incarceration) and indirect 
costs  (e.g. lost productivity, opportunity costs), it has been estimated that the 
annual economic liability associated with substance abuse in the United States 
approaches 500 million dollars3. Thus, In terms of sheer economic costs alone, 
substance abuse is one of the most expensive public health problems that we 
face today and represents a critical target for scientific investigation and 
intervention. Epidemiological investigations have significantly advanced our 
understanding of the specific social and environmental factors that predict the 
development of addiction. In particular, these studies converge to highlight stress 
as a profound risk factor for substance abuse and dependence. Stressors such 
as adverse childhood events – particularly forms of childhood maltreatment – 
increase risk for adult substance abuse in a dose-dependent manner; the 
presence of multiple and/or more severe ACEs  (e.g. repeated childhood sexual 
abuse) predicts lower age of initiation for substance use, increased likelihood for 
developing substance dependence, and increased susceptibility to relapse after 
a period of abstinence 141-154. For example, in a well controlled, large-scale study 
of twins reared together, Kendler and colleagues found that female twins 
exposed to childhood sexual abuse were at significantly greater risk (Odds Ratio 
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>3) for developing substance use disorders compared to unexposed co-twins, 
suggesting a causal link between maltreatment and addiction 151. However, while 
such associations are consistent and robust, the specific neural adaptations 
underlying the link between stress and addiction are still unclear. Therefore, 
elucidating the biological mechanisms through which stress acts to affect risk for 
addiction is an essential step in characterizing its neurobiological risk architecture 
Though human data are sparse, a wealth of preclinical findings argue that 
stress-induced dysregulation of mesocorticolimbic DA circuitry may play a key 
role in mediating the stress-substance abuse linkage. Experimental 
manipulations that induce stress (e.g. perinatal social isolation and maternal 
separation procedures) profoundly alter behavioral responses to drugs of abuse. 
In particular, stress during development is associated with sensitized locomotor 
responses to psychostimulants 155-157 and reward-associated conditioned stimuli 
156, increased behavioral sensitization to psychostimulants 155, 158, 159, enhanced 
acquisition and maintenance of psychostimulant self-administration 160-163 and 
greater ethanol consumption 164. Critically, stress-associated sensitization of 
behavioral responses to drugs of abuse occurs in parallel with a sensitization of 
mesolimbic DA neurochemistry. Stress increases basal extracellular nucleus 
accumbens DA concentrations 157, 165, 166, enhances psychostimulant-induced 
increases in ventral striatal DA levels 157, 165-171, and alters electrophysiological 
responses in prefrontal pyramidal neurons following VTA stimulation 172. Further, 
developmental stress is associated with increased D1 and decreased DAT levels 
in the nucleus accumbens 155, 173, 174, decreased D2 levels in the VTA 164 and 
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mPFC 175, and functional downregulation of D2 receptors in nucleus accumbens 
165. Altogether, these findings clearly demonstrate that stress profoundly 
sensitizes mesocorticolimbic DA system function and behavioral responses to 
drugs of abuse. In considering the proximal biological mechanisms that may 
underpin these effects, it seems reasonable to suggest that stress-linked 
alterations in the mesolimbic reward pathway may be a downstream 
consequence of changes in neural systems that are more proximally involved in 
brain stress response. Indeed, this explanation has empirical support: the effects 
of stress on mesolimbic function appear to be due, in part, to stress-induced 
disruptions in the hypothalamic-pituitary-adrenal  (HPA) stress axis. 
There is considerable evidence that the sensitizing effects of stress on 
mesolimbic DA are mediated by the effect of stress on circulating HPA stress 
hormones, which in turn directly regulate mesolimbic DA function and drug 
seeking behavior176. Importantly, HPA stress hormones strongly regulate 
behavioral responses to drugs of abuse in animal models. For example, 
corticosterone treatment sensitizes locomotor responses to amphetamine177, 
enhances the acquisition of cocaine and amphetamine self-administration in 
rodents 178, 179 and increases reinstatement of extinguished cocaine seeking180. 
Adrenalectomized rats show attenuated locomotor responses to cocaine 181 and 
fail to self-administer cocaine 182; both of these effects are dose-dependently 
reversed by exogenous corticosterone180, 181. Additionally, pharmacological 
blockade of CRH1 (corticotropin releasing hormone receptor 1; also called 
corticotropin releasing factor receptor 1 or CRF1) and glucocorticoid  (GC) 
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receptors reduces cocaine self-administration183-185 and prevents stress- and 
conditioned cue-induced reinstatement of extinguished cocaine seeking186-188. 
Moreover, GCs are necessary for the facilitatory effects of acute stress on drug 
self-administration189, and glucocorticoid receptor knockout mice show drastically 
reduced cocaine self-administration and behavioral sensitization186. Together, 
these data suggest that genetic factors influencing HPA-axis function may impact 
mesolimbic DA sensitivity in humans, and raise the intriguing possibility that 
genetic variability in HPA-axis function may affect risk for addiction, in part, by 
sensitizing mesolimbic DA circuitry.  
Considered in this context, it is enlightening that variability in several 
genes encoding HPA-axis components – including CRH  (encoding the 
corticotropin-releasing hormone), CRH1 (encoding the corticotropin-releasing 
hormone receptor 1), and CRH-BP  (encoding the corticotroping releasing 
hormone binding protein) – have been linked to stress responsiveness, to stress-
induced drug consumption, and to substance abuse risk following exposure to 
childhood maltreatment190-202.  CRH in particular is an intriguing candidate in light 
of several recent findings in non-human primates.  Barr and colleagues reported 
that a functional single nucleotide polymorphism within the promoter region of the 
rhesus CRH gene  (rhCRH -2232CG) predicted alterations in CRH and ACTH 
levels (low baseline CSF CRH and high baseline CSF ACTH), greater behavioral 
disinhibition, and greater alcohol consumption191. This same group subsequently 
demonstrated that a separate functional rhCHR SNP (also located within the 
promoter region: -248CT) predicts enhanced phasic HPA-axis stress reactivity, 
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behavioral inhibition following an acute stressor, and increased stress-induced 
alcohol consumption 190. These findings are particularly intriguing in light of data 
indicating that polymorphic variation in the human CRH gene region is 
associated with trait-like behavioral inhibition203, 204. As both behavioral inhibition  
(anxious temperament) and behavioral disinhibition  (impulsive temperament) are 
associated with enhanced risk for drug dependence6, these data strongly imply a 
role for CRH genetic variability in stress-linked liability for addiction. However, 
there is little human data linking polymorphic variation at the CRH locus to 
addiction-related clinical diagnoses, and virtually no data relating CRH genetic 
variability to addiction-related neurobiological endophenotypes. Given the robust 
association between HPA-axis function and mesolimbic DA system reactivity, 
biological endophenotypes indexing human mesolimbic DA responsiveness 
would be appear to naturally lend themselves to such a line of inquiry.  
To test the hypothesis that human polymorphic variation in CRH affects 
mesolimbic DA system function, we employed positron emission tomography  
(PET) imaging with the high-affinity D2/D3 ligand [18F]fallypride, in concert with 
an amphetamine challenge. This approach provides an in-vivo measure of 
stimulant-induced DA release, which we compared across CRH genotypes in our 
sample of healthy community volunteers.  On the basis of the prior finding by 
Smoller and colleagues (2005) of an association between CRH SNPs and 
behavioral inhibition, we selected the single marker from that study with the 
strongest evidence of association (rs6999100)203. Given our prior work indicating 
that disinhibited temperament is linked to striatal dopaminergic hyper-reactivity, 
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we predicted that the allele that was found to be understransmitted to 
behaviorally inhibited individuals in that family-based association study (the T 
allele) would be associated with enhanced stimulant-induced DA release. 
 
Methods 
Participants 
We studied 59 individuals  (29 males; age range = 18-33, mean = 23; 50 
Caucasian, 5 African-American, 3 Asian, and 1 individual of mixed Caucasian 
descent; Table 1) using a dual-scan placebo-controlled paradigm with 
[18F]fallypride PET and d-Amphetamine  (AMPH).  All participants were 
medically and psychiatrically healthy adults, age 18 to 35, with estimated IQ 
greater than 80.  Subjects were excluded if they had any history of substance 
abuse, current tobacco use, alcohol intake greater than 8 ounces of whiskey or 
equivalent per week, use of psychostimulants  (excluding caffeine) more than 
twice in the subject’s lifetime or at all in past 6 months, any psychotropic 
medication for the past 6 months other than occasional use of benzodiazepines 
for sleep, history of psychiatric illness, significant medical condition, any condition 
which would interfere with MRI or PET studies  (e.g., extreme obesity, 
claustrophobia, cochlear implant, metal fragments in eyes, cardiac pacemaker, 
neural stimulator, and metallic body inclusions or other metal implanted in the 
body which may interfere with MRI scanning, pregnancy, or anemia).  Female 
participants were studied during the early follicular phase of their menstrual 
cycle. 
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Following initial screening, subjects were given an interview of their 
medical history and a structured psychiatric interview  (SCID-NP;109). In addition 
to the regular questions in the non-alcohol substance dependence section of the 
SCID-NP, subjects were asked to indicate the number of times that they have 
taken any drug that they reported having tried, and asked to indicate any usage 
within the last 2 months. Any illicit drug use in the last 2 months was grounds for 
exclusion, even in subjects who did not otherwise meet criteria for substance 
abuse. Urine drug screens were performed to test for the presence of 
amphetamines, cocaine, marijuana, PCP, and opiates, benzodiazepines, and 
barbiturates. 
 
Genotyping 
Saliva was collected from each subject using DNA Genotek Oragene-250 
collection kits. Genomic DNA was extracted per manufacturer’s protocols and 
banked at the Vanderbilt University Center for Human Genetics Research DNA 
Resources Core. Genotyping for rs699100 was conducted by the Vanderbilt DNA 
Resources Core through the use of the TaqMan 5’ exonuclease assay  (Assay 
Table 1. Demographic information for CRH PET Sample   
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ID: C____366649_10). Genotyping for the participants reported in this study was 
performed in two separate genotyping runs, as part of a larger batch of 
genotyping that included DNA collected as part of an unrelated study. The 
genotyping success rate for this marker was high (100%). Allele frequencies 
were as follows: C/C = 2, C/T = 16, T/T = 41, and did not deviate from Hardy-
Weinberg Equilibrium  (p = 0.78).   We found no evidence for an imbalance in 
genotype distribution across sex  (X2 = 2.26, p = 0.32), nor was genotype 
significantly associated with age  (F = 2.16, p = 0.13). However, genotype 
distribution was significantly imbalanced across self-reported ethnicity  (X2 = 
25.12, p < 0.001). Given the low number of C allele homozygotes observed in our 
sample, these individuals were combined with heterozygotes to create a “C-
carriers” group that was used in subsequent analyses. Demographic information 
is reported in Table 1.  
PET 
Image Acquisition and Analysis 
  All PET images were acquired using [18F]fallypride.  ( (S)-N-[ (1-allyl-2-
pyrrolidinyl)methyl]-5- (3[18F]fluoropropyl)-2,3-dimethoxybenzamide), a 
substituted benzamide with very high affinity for D2/D3 receptors110. Unlike other 
D2/D3 ligands, [18F]fallypride allows stable estimates of D2-like binding in both 
striatal and extrastriatal regions111. Our current resolution  (see below) allows 
visualization of [18F]fallypride binding potential in the substantia nigra  
(SN)/ventral tegmental area  (VTA), [for a discussion of the spatial resolution 
requirements for detecting activity in the SN see 112]. However, this resolution 
 52 
does not permit us to cleanly distinguish between different DA cell populations, 
preventing a clear parcellation of the VTA from the neighboring SN, which 
possesses higher levels of D2-like receptors. Previous studies have 
demonstrated good intersubject and intratest-retest reliability for measurement of 
[18F]fallypride binding potential for the DA midbrain at the current resolution113-115. 
[18F]fallypride binds with high affinity to both presynaptic  (“D2-short”) and 
postsynaptic  (“D2-long”) D2-like receptors116. However, because DA receptor 
expression in the midbrain is dominated by the D2-short receptor isoform 117 
variance in [18F]fallypride BPND within the midbrain is presumed to be driven by 
individual differences in these D2-short autoreceptors. 
In addition, [18F]fallypride has been found to be sensitive to endogenous 
DA release 114, 118, particularly in the striatum, making it an ideal ligand for use in 
conjunction with a dual scan strategy that allows assessment of both baseline 
receptor availability and individual differences in induced DA release. Baseline 
binding of [18F]fallypride is also influenced by endogenous DA levels, and thus 
provides a metric of receptor availability, rather than absolute receptor density.  
However, receptor availability has proven a highly useful measure in quantifying 
individual differences in DA functioning, and indeed in some ways may be a more 
relevant variable than receptor density examined in isolation  (as only available 
receptors can be engaged at a given point in time).                                                
Protocols for PET image acquisition and analysis were derived from a 
larger ongoing study and have been previously published 115, 205. Subjects 
received two PET scans using [18F]fallypride. The first scan was a baseline 
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placebo scan; the second scan was performed while the subject received an 
amphetamine  (d-AMPH) challenge. We used a single-blind drug administration 
regimen for the majority of participants  (n = 44); however, we also included in 
our analyses 15 subjects who participated in the study during a pilot phase, and 
who were not blind to drug. We do not observe an imbalance of genotypes 
between blind and non-blind subjects  (Pearson X2 = 0.99, p = 0.61); 
nevertheless, blinded status was included as a nuisance covariate in all analyses 
where it was appropriate to do so  (i.e. that included the 15 non-blind 
participants). PET imaging was performed on a GE Discovery LS scanner 
located at Vanderbilt University Medical Center that was upgraded to a Discovery 
STE system during the course of the study. All subjects received their baseline 
and d-AMPH scans on the same scanner. To ensure the validity of combining 
data across scanners, we performed a voxel-wise analysis comparing DA 
release between the two scanners.  No clusters survived whole brain correction 
at t > 2.5  (lowest cluster-level p-value >.90).  Moreover, no differences were 
observed in our anatomical region of interest, the ventral striatum  (left and right 
VS; both p-values > 0.5). 26 participants were scanned on scanner 1, and 33 
participants were scanned on scanner 2. We did not observe a significant 
imbalance of genotypes between the two scanners  (Pearson Χ2 = 0.36, p = 
0.82; Table 1).  Nevertheless, we included scanner  (i.e. scanner 1 vs. scanner 2) 
as a nuisance covariate in our regression analyses. Following reconstruction 
both scanners had similar in plane and throughplane resolution.  [18F]fallypride 
was produced in the radiochemistry laboratory attached to the PET unit, following 
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synthesis and quality control procedures described in US Food and Drug 
Administration IND 47,245.  Scans were timed to start 3 hours after 0.43mg/kg 
oral d-AMPH administration, which was timed to coincide with the period of peak 
plasma d-AMPH. 3-D emission acquisitions scans were performed following a 
5.0 mCi slow bolus injection of [18F]fallypride  (specific activity greater than 3000 
Ci/mmol). Serial scans were started simultaneously with the bolus injection of 
[18F]fallypride and were obtained for approximately 3.5 hours, with two 15-minute 
breaks for subject comfort. CT transmission scans were collected for attenuation 
correction prior to each of the three emission scans.  
 
Binding Potential Maps 
Each subject’s serial PET scans were first corrected for motion across 
scanning periods and then co-registered to the subject’s structural T1-weighted 
MRI image.  To determine the success of the coregistration in the midbrain, in a 
prior study of 34 subjects115 we manually labeled several landmarks around the 
midbrain, including the posterior edge of the right and left inferior colliculus, the 
anterior-most point of the right and left cerebral peduncle and the interpeduncular 
fossa at z = 10, and the inferiormost point of the supramammillary commissure. 
Of these 34 subjects, all but one showed excellent midbrain coregistration, with 
no tag varying by 2mm in any direction from the mean coordinate of the tag  
(across these 33 subjects, the mean distance in any direction from the average 
tag was 1mm for every tag examined). Given the spatial resolution of the PET 
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images, this degree of misregistration is at the subvoxel level, and would have 
negligible impact on the results. 
Regional D2/D3 binding potential  (nondisplaceable; BPND) was calculated 
on a voxelwise basis using the full reference region method119, with cerebellum 
chosen as the reference region because of its relative lack of D2/D3 receptors120. 
Voxelwise kinetic modeling was executed using Interactive Data Language. Prior 
studies in our lab indicate that the reference region method produces binding 
potential estimates that are in close agreement with estimates derived from 
Logan plots 121 using a metabolite corrected plasma input function. Because 
[18F]fallypride binding values exhibit significant variability across different regions  
(e.g., striatum vs. prefrontal cortex; PFC), we used variance estimates at the 
voxelwise level rather than the pooled variance used in typical parametric 
analyses 122. Individual images of percent-change in [18F]fallypride binding from 
placebo to amphetamine  (representing percent-change in DA release) were 
created by subtracting each subject’s amphetamine scan from their placebo scan 
and dividing the resulting imaging by the placebo scan, using the “imcalc” image 
math routine in SPM5. 
 
Region of Interest Analyses 
 Based largely on the preclinical research described above showing that 
stress-induced sensitization of behavioral and ventral striatal dopamine 
responses to stimulants may be mediated by glucocorticoid signaling, we limited 
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our analysis of the effects of CRH genetic variation on stimulant-induced DA 
release to the ventral striatum. To that end, we constructed an anatomical  
 
 
     
 
VS region of interest (ROI) by manually editing the striatum ROI derived from the 
LONI Probabilistic Brain Atlas 40  (LPBA40)125 according to the criteria outlined 
in Mawlawi et al. (2001)127. To permit subregion-selective assessment of CRH 
genotype effects within the striatum, we parcellated the LPBA40 striatum ROI 
into 4 additional striatal subregion ROIs: dorsal caudate rostral to the anterior 
commissure  (AC), dorsal putamen rostral to the AC, post-commissural caudate, 
and post-commissural putamen, also using previously described criteria126, 127  
(Figure 1).  Percent-change values were averaged across all voxels within left 
Figure 1. Striatal Regions of Interest (ROIs). ROIs rendered on a 
T1-weighted reference image, with a coronal slice at Y = 11 (MNI 
space). ROIs defined by anatomical criteria of Mawlawi et al (2001). 
Only pre-commisural ROIs are shown.   
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and right ROIs to create a single percent-change value for each individual’s ROI 
mask.   
 
Personality Measures 
 Impulsivity was assessed with the 30-item Barratt Impulsiveness Scale, 
version 11  (BIS-11)206, which is one of the most widely used self-report 
measures of impulsive personality traits207-216. The BIS-11 yields scores for 6 
subscales (Attention, Motor, Self-Control, Cognitive Complexity, Perseverance, 
and Cognitive Instability) and 3 factors (Attentional, Motor, Non-Planning), as well 
as a full-scale score. We used full-scale scores only for correlation analyses. The 
PPI comprises 187 multiple-choice items, and yields a total score, as well as 
scores for eight subscales: Impulsive Nonconformity, Blame Externalization, 
Machiavellian Egocentricity, Carefree Nonplanfulness, Stress Immunity, Social 
Potency, Fearlessness, and Coldheartedness. Based on the work of Benning 
and colleagues, and as reported previously in our work63, 217, Impulsive-Antisocial  
(PPI-IA) factor scores were obtained by summing z-scores for the Machiavellian 
Egocentricity, Blame Externalization, Carefree Nonplanfulness, and Impulsive 
Nonconformity subscales. Within our PET sample, 44 participants had both 
personality and genetic data  (13 C-carriers and 31 T/T individuals). BIS-11 
scores in these 44 participants ranged from 43 to 84, with a mean  (standard 
deviation) of 58.37  (9.37).  For the PPI, mean, standard deviation, and range for 
each of the scales comprising the PPI-IA score were: 62.61, 12.33, 40-89  
(Machiavellian Egocentricity); 28.59, 6.7, 19-41  (Blame Externalization); 35.02, 
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6.66, 23-51  (Carefree Nonplanfullness), 35,3, 8.38, 22-57  (Impulsive 
Nonconformity).  
 
Statistical analysis 
Statistical analyses using were performed using SPSS 17.0 for the 
Macintosh. To test for genotype effects on VS DA release, we used a linear 
regression model with rs6999100 genotype  (dummy coded as 1 = C-carriers, 2 = 
T/T) as a predictor of % change in DA release (separate models for left and right 
VS). For each ROI, we used the mean percent-change in DA release value 
averaged across all voxels within that ROI  (described above). PET scanner, 
ethnicity, and sex were included in the regression model as nuisance covariates. 
In follow-up control analyses, we added blinding status and VS BPND  as 
additional nuisance covariates. Two-tailed tests were used, with alpha = 0.05.  
To test for genotype effects outside of our primary VS region of interest, 
we performed a multivariate analysis of covariance  (MANCOVA) using CRH 
genotype as a predictor of AMPH-induced DA release within left and right VS, 
dorsal caudate, dorsal putamen, post-commisural caudate, and post-commisural 
putamen  (ROI creation described above). Sex, ethnicity, PET scanner and 
blinding status were included as nuisance covariates. 
Whole-brain genotype-effect analyses were performed using SPM5 
running on Matlab R2007b for the Macintosh. We used a linear regression model 
with rs6999100 genotype  (dummy coded as 1 = C-carriers, 2 = T/T) as a 
predictor of voxelwise DA release  (i.e. we used voxelwise images of percent-
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change in DA release following AMPH administration, as described above). 
Scanner, ethnicity, blinding status and sex were included as nuisance covariates. 
To test for genotype effects, we used an uncorrected exploratory threshold of p < 
0.005, coupled with a cluster-extend threshold of 20 voxels.  
We used two MANCOVA analyses to investigate the impact of CRH 
genotype on impulsive temperament. For the BIS-11 analysis, CRH rs6999100 
genotype was included as a predictor of BIS-11 total, subscale (Attention, Motor, 
Self-Control, Cognitive Complexity, Perseverance, and Cognitive Instability) and 
factor scores  (Attentional, Motor, Non-Planning), with sex and ethnicity included 
in the model as nuisance covariates. For the PPI analysis, CRH rs6999100 
genotype was included as a predictor of PPI total, subscale  (Machiavellian 
Egocentricity, Social Potency, Fearlessness, Coldheartedness, Impulsive 
Nonconformity, Blame Externalization, Carefree Nonplanfulness, and Stress 
Immunity) and the PPI-IA factor scores, with sex and ethnicity included in the 
model as nuisance covariates. For both analyses, two-tailed tests were used, 
with alpha = 0.05. Reported p-values obtained from the test of Between-Subjects 
effects.  
 To test for a relationship between impulsive temperament and VS DA 
release, we performed two separate partial correlation analyses between bilateral 
VS DA release and BIS-11 total scores and between bilateral VS DA release and 
PPI-IA factor scores. In both cases, sex and PET scanner were used as 
covariates  (personality data was only available for participants who were blind to 
drug administration). Two-tailed tests were used, with alpha = 0.05.  
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Results 
 
Descriptive and inferential statistics for VS BPND and AMPH-induced DA 
release 
Across the entire sample, mean (standard deviation) baseline BPND values 
in the left and right VS ROIs were 22.04  (3.71) and 21.01  (3.77). Mean post-
AMPH BPND values in the left and right VS ROIs were 20.79  (3.77) and 19.94  
(3.68). Repeated-Measures Analysis of Variance  (ANOVA) confirmed a 
significant reduction in BPND in both left  (F1,58 = 43.52, p = 0.0000000139) and 
right VS  (F1,58 = 36.36, p = 0.00000012) following AMPH administration  (Figure 
2).  
 
 Figure 2. Amphetamine significantly reduces [18F]fallypride binding potential in ventral striatum. Binding potential (BPND) values on 
placebo (PLAC) and amphetamine (AMPH) depicted for left and 
right ventral striatum in 59 participants. 
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CRH Genotype effect on VS DA release 
To test for an association between CRH rs6999100 genotype and AMPH-
induced DA release, we regressed our participants’ genotypes against their 
mean percent-change in DA release within left and right VS ROIs. This analysis 
revealed that rs699100 genotype was a significant predictor of AMPH-induced 
DA release in both left  (β = 0.38, p = 0.003) and right  (β = 0.41, p = 0.002) VS, 
such that T/T individuals showed significantly greater DA release in response to 
AMPH compared to C-carriers  (Figure 3). These effects remained significant  (p 
< 0.01) when blinding status was included in the regression model.  We did not 
find a significant effect of CRH genotype on baseline D2/D3 binding in either left 
or right VS  (both p-values > 0.5), and CRH genotype remained a significant 
predictor of AMPH-induced DA release even when controlling for baseline VS 
D2/D3 levels  (both p-values < 0.005)
 
 
Figure 3. Effects of CRH rs6999100 genotype on AMPH-induced DA 
Release in left and right ventral striatum. Error bars indicate ± 1 
standard error of the mean. 
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Striatal subregional specificity of CRH effects 
 While our a-priori hypothesis centered on a potential impact of CRH 
genetic variability in VS, we endeavored to test empirically the subregional 
selectivity for CRH rs6999100 effects within the striatum.  To that end, we 
examined genotype effects within the following striatal subregions: (left and right) 
VS, dorsal caudate, dorsal putamen, post-commisural caudate, and post-
commisural putamen. This analysis confirmed an effect for CRH genotype on DA 
release in left and right VS  (p = 0.005, left VS; p = 0.003, right VS). In addition, 
we found a nominally significant effect in dorsal putamen  (left and right, both p-
values = 0.04); however this effect did not survive a Benjamini-Hochberg false-
discovery rate  (FDR) correction for multiple comparisons 218, which yielded 
adjusted p-values of 0.1 for the effect of genotype on left and right dorsal 
putamen. We did not find even nominally significant effects of CRH genotype on 
AMPH-induced DA release in any of the other ROIs  (p-value range: 0.08-0.91).  
 
Whole brain exploratory analysis 
To examine unhypothesized effects of CRH rs6999100 genotype outside 
of the striatum, we performed a whole-brain regression analysis in SPM5. At a 
liberal, uncorrected exploratory statistical threshold, we did not observe any 
extrastriatal voxels in which AMPH-induced DA release was significantly 
predicted by genotype. In addition, we investigated the impact of CRH genetic 
variation on baseline D2/D3 binding. At the same exploratory threshold noted 
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above, we found no significant effect of variability at the CRH rs6999100 locus on 
D2/D3 levels anywhere in the brain.  
 
Relationships between CRH genotype, Impulsive Traits, and DA Release 
 Taken together, our PET findings indicate that CRH genetic variation 
selectively affects AMPH-induced DA release within the VS. Specifically, T-allele 
homozygotes demonstrated sensitized VS DA responses to AMPH, compared to 
C-allele carriers. Given that the T-allele was found to be under-transmitted to 
individuals with behavioral inhibition in a prior study (i.e. the T-allele – and the 
common haplotype it monitors – was less likely to be found in chromosomes of 
behaviorally inhibited individuals), we sought to test for an association between 
CRH genetic variation and disinhibited temperament. To that end, we regressed 
rs699100 T-carrying status against scores on two trait measures of impulsivity  
(BIS-11 and PPI) that have been shown previously to index risk for addiction. We 
did not find compelling evidence for an association between CRH genotype and 
these measures in our small sample. For PPI total, subscale, and PPI-IA factor 
scores, all p-values were > 0.25, with the exception of Carefree Nonplanfullness, 
where the nominal p-value = 0.055  (T/T mean = 36.23, C-carrier mean = 32.08). 
For BIS-11 total and subscale scores, all p-values were > 0.3. 
 However, as we and others have shown previously that striatal DA 
responses to AMPH is positively correlated with these traits, we endeavored to 
confirm the relevance of increased DA release in T/T individuals to risk for 
behavioral disinhibition by demonstrating an association between DA release and 
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impulsive traits in the current sample. Consistent with our prior findings in a 
smaller sample, we found a positive relationship between left and right VS DA 
release and BIS-11 total scores (r = 0.34, p = 0.03, left VS; r = 0.44, p = 0.004, 
right VS) and between left and right VS DA release and PPI Impulsive-Antisocial 
factor scores  (r = 0.4, p = 0.009, left VS; r = 0.54, p = 0.0003, right VS).  This 
suggests that, even though we may have been underpowered to detect an 
association between rs6999100 and impulsive temperament, T-allele carriers 
showed a pattern of neurobiological response to AMPH that is, in turn, 
associated with high levels of impulsivity.  
 
Discussion 
 Here, we report novel evidence that genetic variation in glucocorticoid 
signaling can impact striatal DA responses to a stimulant drug of abuse. In 
particular, we found that homozygous carriers of the CRH rs6999100 T-allele – 
previously demonstrated to be undertransmitted to individuals with behavioral 
inhibition – show sensitization of striatal DA responses to AMPH, a response 
pattern that is itself linked to behavioral disinhibition. Of note, these data accord 
well with prior research on genetic variability at the CRH1, which encodes the 
cognate receptor for CRH  (CRH1). CRH1 expression is regulated by stress 219-
221 and CRH1 activity is known to be important for drug-induced sensitization189, 
222, 223. Genetically mediated variation in CRH1 function is associated with HPA-
axis hypersensitivity 199, 224, risk for stress-induced drug relapse in animal 
models194, and with enhanced penetrance of environmental risk in predisposing 
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the development of alcohol abuse200, 201, 225. The current data add to a growing 
literature which, as a whole, endorses the notion that genetic variation in HPA-
axis factors linked to stress responsivity can contribute to risk for addiction by 
affecting mesolimbic DA system function.  
 In considering a biologically tractable mechanism for the observed 
association between CRH genotype and DA function, we note that there is ample 
evidence that the impact of glucocorticoids on addiction-related behaviors is 
subserved by their direct effects on mesolimbic DA neurotransmission. 
Corticosterone elevates DA release in the NAcc and stimulates locomotor activity 
in a DA dependent manner226, and stress-induced sensitization of DA release 
and behavioral responses to drugs of abuse is GC dependent227, 228. By contrast, 
adrenalectomy and glucocorticoid receptor antagonism decrease basal NAcc DA 
levels and suppress NAcc DA release and locomotor activity induced by drugs of 
abuse and acute stress226 229, 230. Crucially, CRH has been shown to stimulate 
NAcc DA release by acting on CRH1 receptors 231, 232 and the ability of cocaine 
to increase DA efflux in NAcc is blocked by pharmacological antagonism of 
CRH1 receptors233 in a manner that is correlated with changes in VTA firing234, 
suggesting that GCs modify DA signaling by acting directly on midbrain DA 
neurons. Supporting this notion, GC and CRH1 receptors are expressed on 
DAergic neurons of the VTA 235, 236, and both corticosterone and CRH potentiate 
NMDA-mediated VTA synaptic transmission237, 238. Further, CRH has been 
shown to act on VTA CRH1 receptors to increase VTA firing239 and to elicit 
increased calcium release from intracellular stores240, implicating GCs in stress-
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induced neuroplastic processes within the DAergic midbrain. It is thus noteworthy 
that acute stress results in GR-dependent VTA synaptic adaptations that are also 
common to drugs of abuse237, 238. On the whole, these findings emphasize the 
fact that stress-associated sensitization within the mesolimbic DA system is 
mediated by stress-induced dysregulation of the HPA-axis, and lend credence to 
the idea that genetically-mediated differences in stress hormone signaling could 
affect risk for addiction by dysregulating mesolimbic DA function.    
 This study has several important limitations. First, the functional effects of 
the rs6999100 variant are unclear at this time. While this SNP has been identified 
as a CRH variant, it is in fact located within an intronic region in a gene  
(TRIM55) that is located immediately adjacent to the 3’ end of CRH on the 
forward strand of chromosome 8q13.1  (Figure 4). As TRIM55  (also known as 
MURF-2 or RNF29) encodes a muscle-specific zinc finger protein241, it is unlikely 
that the functional effects of rs6999100 allelic variation on mesolimbic DA are 
due to alterations in TRIM55 function or expression. However, it does seems 
reasonable to suggest that rs699100 may not itself be the causative variant 
driving the observed genotype-linked changes in DA signaling, but rather may in 
linkage disequilibrium (LD) with the true causative SNP, perhaps located within 
the CRH gene region proper. Indeed, rs6999100 is found within a substantial 
block of LD that encompasses the entire CRH gene, and extends nearly 31kb 
into its upstream region  (Haploview 4.2, Version 3, Release 2, CEU population 
data; Figure 4).   
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Second, we did not find a significant association to trait phenotypes linked 
to addiction. This negative association may be due to the small sample size in 
this study  (44 individuals had both personality and genetic data) compared to 
many other candidate gene association studies of traits, where sample size 
commonly exceeds 100 participants. However, we did observe that CRH 
variation was linked to enhanced DA release, which was in turn linked to 
impulsivity. While this does support our contention that the higher level of striatal 
DA released in response to AMPH in rs6999100 T/T participants  (approximately 
6% more compared to C-carriers) is relevant to individual differences in risk for 
disinhibitory psychopathology, a direct association would provide a more 
Figure 4. Exonic structure and genomic context of CRH gene on chr.22. 
Depicts linkage disequilibrium structure of the region surrounding CRH 
gene, as well as the position of HapMap SNPs (Release 3, Version 2). 
rs6999100 highlighted with red box and genomic position indicated with 
blue arrow.  
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compelling form of evidence. To that end, we suggest that these findings 
nominate CRH for focused association analysis targeting externalizing 
phenotypes such as addiction, antisocial personality disorder, and attention-
deficit/hyperactivity disorder. By the same token, given that other groups have 
found a significant interaction between allelic variation in the CRH1 receptor and 
environmental stress in predicting risk for alcohol abuse, and in light of empirical 
support for a similar interaction with CRH in non-human primates, the present 
data strongly highlight the need to more thoroughly explore the possibility of 
interplay between CRH genetic variability and environmental stressors in 
promoting substance abuse.   
Third, though this is one of the largest studies of stimulant-induced DA 
release ever reported, the sample is extremely small by the standards of genetic 
association. While the expense of the dual-scan PET approach ($8-10k/subject) 
tends to prohibit large datasets, multi-site replication and data pooling for meta-
analytic approaches would be useful in confirming the effects reported here, and 
may help to circumvent some of the traditional limits to PET sample size placed 
by cost. In addition, our sample was ethnically heterogeneous, raising the 
possibility that our observed associations are due to population admixture. The 
decision to include non-Caucasian participants was motivated by a desire to 
obtain as large a sample size as possible, and our study recruitment was blind 
with respect to ethnicity. We note that we included self-reported ethnicity as a 
nuisance covariate in all of our general linear model analyses, and also that our 
reported effects of CRH variability on VS DA release remain significant even 
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when non-Caucasians are excluded from analysis  (all p’s < 0.01). However, we 
acknowledge that we cannot completely rule out the possibility of spurious 
association due to cryptic ethnic stratification. The use of ancestry informative 
markers in future studies will enable us to detect population structure in our data 
and correct for its effects.     
 In conclusion, we report first-ever evidence that genetically-mediated 
variation in human HPA stress axis signaling affects ventral striatal DAergic 
responses to the administration of a stimulant drug of abuse. Homozygosity for 
the rs6999100 T allele – previously found to be undertransmitted in individuals 
with behavioral inhibition – predicted relatively sensitized ventral striatal DA 
release in response to amphetamine, the magnitude of which was in turn 
associated with higher levels of impulsive traits. These findings buttress prior 
preclinical associations of Crh variants to addiction-linked behaviors, and 
nominate the human CRH gene for more thorough phenotypic analysis.  
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CHAPTER IV 
 
OBESITY-LINKED GENETIC VARIABILITY IN LEPTIN SIGNALING PREDICTS 
ALTERATIONS IN MESOLIMBIC DOPAMINE NEUROCHEMISTRY 
 
 Obesity – defined as a body mass index of ≥ 30 kg/m2 – predicts increased 
morbidity from a range of somatic illnesses, including hypertension, type II 
diabetes, coronary heart disease, stroke, and a number of distinct cancers242. 
Current estimates suggest that fully 1/3 of the U.S. population meets the criteria for 
obesity243. Given its high prevalence and associated health risks, it is perhaps 
unsurprising that obesity is estimated to cost nearly $150 billion per year244. 
Further, these costs are likely to increase: obesity rates have increase dramatically 
over the past 30 years and continue to rise in some especially high-risk 
demographics245. Taken together, the cost in dollars and quality of life marks 
obesity as a significant public health problem that is worthy of scientific 
investigation and intervention.  
 While classic accounts tended to construe obesity strictly in terms of 
nutrition and metabolism, current conceptualizations stress the psychological 
pathomechanisms that characterize the pattern of compulsive, non-homeostatic 
consumption of palatable (high-fat/high-calorie) foods that is associated with the 
development and maintenance of obesity. Of note, it is on the basis of this 
compulsive behavioral component that some have called for obesity to be included 
in the next revision of the Diagnostic and Statistical Manual  (DSM-V) as a form of 
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addiction246. Indeed, to a large extent, focus on the psychopathological dynamics 
that underlie obesity – in particular, obesity that is caused by an excessive 
motivational drive for high-fat/high-calorie food – centers on the striking parallels 
between obesity and drug addiction247, 248. Both addiction and obesity involve a 
transition from the volitional or recreational pursuit and intake of a substance  (a 
drug or palatable food) that is valued because of the subjective pleasure produced 
by its consumption, to the compulsive pursuit of that substance that persists 
despite adverse consequences and the loss of control over its intake246. Indeed, 
Volkow and O’Brien have argued that each of the DSM-IV criteria for substance 
dependence – tolerance; withdrawal; overconsumption; desire for and failure to 
achieve a reduction in usage; significant time spent obtaining, consuming and 
recovering from the substance; abdication of social, occupation, and recreational 
activities due to substance use; and persistent use despite knowledge chronic 
physical and/or psychological problems caused by use – have parallels in 
obesity246. For example, considering tolerance and withdrawal, an obese individual 
may be forced to increase the amount of food they consume to reach satiety and 
may experience distress during periods of abstinence from their desired palatable 
food  (i.e. during dieting). Intriguingly, obese individuals demonstrate a personality 
and neuropsychological profile that is markedly similar to individuals with 
substance use problems, including impulsive decision-making on the Iowa 
Gambling Task  (IGT), greater delay-discounting, more impulsivity, and higher 
novelty seeking scores on the Temperament and Character Inventory  (TCI)249-252. 
Moreover, relationships between obesity and impulsivity can be observed in early 
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childhood and adolescence253, 254, suggesting that they co-develop. On the whole, 
the conspicuous psychopathological parallels between obesity and substance 
abuse tend to validate the construal of obesity as form of addiction or dependence  
(i.e. to palatable food), and raise the possibility of common biological origins.  
Indeed, such parallels strongly imply the presence of shared 
pathophysiology between the two disorders, and preclinical research highlights 
dysregulation within mesolimbic dopamine reward circuitry as a potential common 
neurobiological factor that may underpin both substance abuse and obesity. All 
drugs of abuse act to promote the release of dopamine from nerve terminals in the 
ventral striatum, both directly via stimulatory effects on dopaminergic neurons of 
the substantia nigra and ventral tegmental area or by facilitating transmitter efflux 
from presynaptic boutons  (or, alternatively, through direct inhibitory effects on 
synaptic dopamine clearance), and indirectly by inhibiting the influence of 
GABAergic interneurons on VTA activity255-257. Palatable food consumption 
appears to impinge on mesolimbic DA reward circuitry as well: several studies 
have shown that exposure to palatable food – and to food-conditioned cues – 
enhances ventral striatal DA release258-260. This regulation of striatal DA by food is 
mediated through the impact of palatable food on opioid signaling in GABAergic 
striatal medium spiny neurons (MSNs) and in GABAergic interneurons that 
synapse on DAergic VTA neurons11, 261-263, and by downstream effects of palatable 
food on circulating levels of peptides that modulate dopaminergic function  (e.g. 
leptin, insulin)264, 265. Importantly, instrumental responding for both food and drug 
rewards is abolished following pharmacological blockade of striatal DA receptors or 
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lesioning of striatal DA nerve terminals266, demonstrating the shared requirement 
of striatal DA function for feeding-related and drug-related motivational drive.    
 Human neuroimaging data also emphasize common patterns of mesolimbic 
DA dysfunction in obesity and addiction. For example, food cravings  (induced by 
dietary manipulation, in combination with a cue-induction technique) produce a 
pattern of brain activation in mesolimbic DA reward circuitry that is strikingly similar 
to that produced during drug craving267. This circuitry is engaged following the 
presentation of high calorie  (but not low calorie) food in obese individuals268, and 
in non-obese subjects with temperamental risk factors for obesity269. Importantly, a 
recent prospective study showed that mesolimbic response to high calorie food 
predicts future increases in BMI270, suggesting that alterations in mesolimbic 
sensitivity to natural rewards are involved in the etiology of obesity. Remarkably, 
obesity is also associated with reduced NAcc D2 receptor density271 – mirroring 
findings in drug addicted individuals272-275 – and in animals that have developed 
compulsive patterns of palatable food intake276. Further, an addiction-linked variant 
in the D2 receptor gene that is associated with lower striatal D2 expression also 
modulates mesolimbic reward response to high calorie foods in obese subjects270. 
Taken together, these findings show that a natural reward  (palatable food) 
activates the mesolimbic DA reward system in a manner that parallels drugs of 
abuse, and that individuals who demonstrate behavioral dyscontrol over natural 
rewards present with changes in mesolimbic DA neurochemistry and 
neurophysiology that echo changes seen in individuals who abuse drugs.  
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 The striking degree of psychopathological and neurobiological synchrony 
between obesity and addiction suggests the possibility of shared 
etiopathophysiological mechanisms. Though the risk architectures of substance 
abuse and obesity are complex, heritability estimates range from 40%-60% for 
addiction5, 6 and 45%-85% for BMI277, 278, implying an important role for genetic 
susceptibility factors in both disorders. While empirical data on shared genetic 
variance between addiction and obesity are currently unavailable, it seems 
reasonable to propose – on the basis of the parallels highlighted above – that a 
shared genetic risk factor (or set of genetic risk factors) may act in a pleiotropic 
fashion to increase susceptibility to both addiction and obesity. This notion is also 
supported, in part, by evidence of comorbidity between the two disorders: 
individuals seeking treatment for obesity are significantly more likely to present 
with substance use problems compared to a general population sample279.  
If it is true that the psychopathological and neurobiological overlap reflects 
shared genetic risk between obesity and addiction, it may be the case that this 
common risk factor exerts a relatively deleterious influence over a neurobiological 
pathway that is jointly impacted in both disorders, with environmental factors 
pushing the expression of psychopathology in one direction or the other  (i.e. 
towards obesity versus substance abuse). This would accord with the known 
importance of disorder-general genetic factors and disorder-specific environmental 
factors in predisposing disease outcomes in externalizing psychopathology280. For 
example, social and cultural dynamics clearly play a role in the development of 
both obesity and addiction, but these factors do not necessarily overlap. A factor 
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that influences an individual's level of physical activity and/or access to high-
calorie/high-fat foods  (especially processed and junk food) would, on a 
background of this common genetic risk, likely predispose the development of 
obesity but not  (necessarily) addiction.  
A putative common susceptibility factor should affect neurophysiological 
domains that are relevant to both disorders  (e.g. motivation) rather than those that 
would be specific to one or the other  (e.g. taste-related sensory processing). One 
avenue for exploring this possibility is to examine the impact of specific genetic risk 
factors for one disorder or the other on neurobiological phenotypes that are linked 
to both disorders. For example, one could probe the impact of an obesity-linked 
genetic variant on a measure of brain function that has been shown previously to 
be affected in both obesity and addiction. Such an effect, if found, would nominate 
the obesity-linked variant for enhanced phenotypic investigations in addiction. In 
this chapter we adopt this strategy, focused on characterizing the impact of an 
obesity-linked genetic variant in the leptin receptor gene  (LEPR) on mesolimbic 
DA system function. 
Leptin, perhaps the best-known and most well-characterized hormonal 
regulator of food intake, is a 16 kDa protein comprised of 146 amino acids281, 282. 
Secreted from adipose tissue, leptin crosses the blood brain barrier to exert central 
effects by acting on it cognate receptor. The leptin receptor  (Lepr) is a one 
transmembrane domain spanning protein that is coupled to the Janus kinase-
signal transducer and activation of transcription  (JAK-STAT) pathway, and which 
belongs to the cytokine receptor superfamily283-286. The leptin signaling pathway 
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was the first genetic factor linked to obesity: a series of landmark studies 
examining two strains of spontaneously obese mice  (so called ob and db mice) 
demonstrated that mutations in the leptin and leptin receptor genes were 
responsible for producing the obesity and hyperphagia phenotypes281, 283, 287-289. In 
both cases, the mutations resulted in impaired leptin signaling. Subsequent 
investigations suggested that peripheral leptin levels – which rise after feeding – 
act on hypothalamic leptin receptors as a satiety signal to inhibit feeding activity, 
explaining the association between leptin deficiency and obesity281.However, more 
recent work suggests that leptin’s modulatory impact on mesolimbic DA function 
may critically influence its effects on feeding behavior. Functional receptors for 
leptin are prominently expressed in the VTA, particularly in neurons that co-
express tyrosine hydroxylase290, 291, and local infusion of leptin into the VTA 
suppresses food consumption in a dose-dependent manner291. Further, leptin 
reduces the firing rate of VTA DA neurons in vivo and in vitro VTA slice 
preparations, and leptin infusion decreases synaptic DA concentrations in the 
NAcc291, 292. Critically, VTA-specific leptin receptor knockdown increases food 
intake, locomotor activity and sensitizes behavioral responses to food reward291.  
Human studies confirm that genetically mediated variability in leptin 
signaling alters human feeding behavior. Rare mutations in the leptin  (LEP) and 
leptin receptor  (LEPR) genes have been identified in several families, resulting in 
congenital leptin deficiency and marked obesity293-295. Of note, leptin replacement 
therapy in LEP mutation carriers partially rescues the obese phenotype by 
reducing food intake in a manner that is correlated with changes in ratings of food 
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“wanting296.” Crucially, functional neuroimaging studies suggest that these changes 
are mediated by LEP-associated changes in the responsiveness of striatal reward 
circuitry to appetitive food stimuli297, 298. While congenital leptin deficiency is 
extremely rare, common single nucleotide polymorphisms (SNPs) in LEP and 
LEPR have been linked to increased risk for obesity, elevated body mass index, 
risky eating behaviors, and type-II diabetes299-318. Thus, common individual genetic 
differences in leptin signaling affect motivation to obtain food reward, and may do 
so by altering the reactivity of striatal reward circuitry. Given that DA is a powerful 
regulator of feeding motivation  (as detailed above), and taking into account the 
known role for leptin in modulating mesolimbic DA circuit activity, these findings 
strongly suggest that obesity-associated variants in leptin signaling genes may 
affect risk by altering mesolimbic DA reactivity. Further, as proposed above, if true 
– that is, if an obesity-linked variant affects mesolimbic DA system function – this 
would nominate that variant as a novel putative risk variant for addiction. To test 
this notion, we examined the effect of two nonsynonymous coding variants in the 
LEPR gene with prior positive associations to BMI and obesity: rs1137101  
(Q233R) and rs137100  (K109R)319 on a measure of striatal DA function  
(amphetamine-induced DA release) that is sensitive to individual differences in risk 
for addiction.  
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 Methods 
Participants 
We studied 59 individuals  (29 males; age range = 18-33, mean = 23; 50 
Caucasian, 5 African-American, 3 Asian, and 1 individual of mixed Caucasian 
descent; Table 1) using a dual-scan placebo-controlled paradigm with 
[18F]fallypride PET and d-Amphetamine  (AMPH).  Body Mass Index  (BMI) data 
were available for 43 participants with rs137100 genotype data and 42 participants 
with rs137101 genotype data. All participants were medically and psychiatrically 
healthy adults, age 18 to 35, with estimated IQ greater than 80.  Subjects were 
excluded if they had any history of substance abuse, current tobacco use, alcohol 
intake greater than 8 ounces of whiskey or equivalent per week, use of 
psychostimulants  (excluding caffeine) more than twice in the subject’s lifetime or 
at all in past 6 months, any psychotropic medication for the past 6 months other 
than occasional use of benzodiazepines for sleep, history of psychiatric illness, 
significant medical condition, any condition which would interfere with MRI or PET 
studies  (e.g., extreme obesity, claustrophobia, cochlear implant, metal fragments 
in eyes, cardiac pacemaker, neural stimulator, and metallic body inclusions or 
other metal implanted in the body which may interfere with MRI scanning, 
pregnancy, or anemia).  Female participants were studied during the early follicular 
phase of their menstrual cycle. See Table 1 for demographic information.  
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Following initial screening, subjects were given an interview of their medical 
history and a structured psychiatric interview  (SCID-NP;109). In addition to the 
regular questions in the non-alcohol substance dependence section of the SCID-
NP, subjects were asked to indicate the number of times that they have taken any 
drug that they reported having tried, and asked to indicate any usage within the 
last 2 months. Any illicit drug use in the last 2 months was grounds for exclusion, 
even in subjects who did not otherwise meet criteria for substance abuse. Urine 
drug screens were performed to test for the presence of amphetamines, cocaine, 
marijuana, PCP, and opiates, benzodiazepines, and barbiturates.  
 
Genotyping 
Saliva was collected from each subject using DNA Genotek Oragene-250 
collection kits. Genomic DNA was extracted per manufacturer’s protocols and 
banked at the Vanderbilt University Center for Human Genetics Research DNA 
Resources Core. Genotyping for rs1137101 and rs1137100 was conducted by the 
Vanderbilt DNA Resources Core through the use of the Sequenom massARRAY 
genotyping platform, based on a single-base primer extension reaction coupled 
Table 1. Demographic information for LEPR PET Sample   
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with mass spectrometry. Genotyping for the participants reported in this study was 
performed in two separate genotyping runs, as part of a larger batch of genotyping 
that included DNA collected as part of an unrelated study. The genotyping success 
rate for rs1137101 and rs1137100 for these 59 participants across the two 
genotyping runs was high  (98.3% and 96.6%, respectively), leaving 58 
participants with both PET data and rs1137101 genotype and 57 participants with 
both PET data and rs1137100 genotype. Allele frequencies were as follows: A/A = 
29, A/G = 20, G/G = 9  (rs1137101) and A/A = 29, A/G = 19, G/G = 9 (rs1137100), 
and did not deviate from Hardy-Weinberg Equilibrium (p’s > 0.05).  The two 
markers were in low-moderate linkage disequilbrium  (D’ = 0.51) in our sample. We 
found no evidence for an imbalance in genotype distribution across sex  
(rs1137101: X2 = 3.6, p = 0.17; rs1137100: X2 = 3.68, p = 0.2) or PET scanner  
(rs1137101: X2 = 4.15, p = 0.13; rs1137100: X2 = 1.01, p = 0.6), nor was genotype 
significantly associated with age  (rs1137101: F = 0.57, p = 0.57; rs1137100: F = 
0.007, p = 0.93). Genotype distribution was significantly imbalanced across self-
reported ethnicity and blinding status for rs1137101  (X2 = 18.67, p = 0.005; X2 = 
11.64, p = 0.003) but not rs1137100  (X2 = 8.22, p = 0.22; X2 = 0.97, p = 0.62). 
Given the low number of G/G individuals for both markers, these participants were 
grouped with heterozygotes into a G-carrier group for subsequent analyses.  
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PET 
Image Acquisition and Analysis 
  All PET images were acquired using [18F]fallypride.  ( (S)-N-[ (1-allyl-2-
pyrrolidinyl)methyl]-5- (3[18F]fluoropropyl)-2,3-dimethoxybenzamide), a substituted 
benzamide with very high affinity for D2/D3 receptors110. Unlike other D2/D3 
ligands, [18F]fallypride allows stable estimates of D2-like binding in both striatal and 
extrastriatal regions111. Our current resolution  (see below) allows visualization of 
[18F]fallypride binding potential in the substantia nigra  (SN)/ventral tegmental area  
(VTA), [for a discussion of the spatial resolution requirements for detecting activity 
in the SN see 112]. However, this resolution does not permit us to cleanly 
distinguish between different DA cell populations, preventing a clear parcellation of 
the VTA from the neighboring SN, which possesses higher levels of D2-like 
receptors. Previous studies have demonstrated good intersubject and intratest-
retest reliability for measurement of [18F]fallypride binding potential for the DA 
midbrain at the current resolution113-115. [18F]fallypride binds with high affinity to 
both presynaptic  (“D2-short”) and postsynaptic  (“D2-long”) D2-like receptors116. 
However, because DA receptor expression in the midbrain is dominated by the D2-
short receptor isoform 117 variance in [18F]fallypride BPND within the midbrain is 
presumed to be driven by individual differences in these D2-short autoreceptors. 
In addition, [18F]fallypride has been found to be sensitive to endogenous DA 
release 114, 118, particularly in the striatum, making it an ideal ligand for use in 
conjunction with a dual scan strategy that allows assessment of both baseline 
receptor availability and individual differences in induced DA release. Baseline 
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binding of [18F]fallypride is also influenced by endogenous DA levels, and thus 
provides a metric of receptor availability, rather than absolute receptor density.  
However, receptor availability has proven a highly useful measure in quantifying 
individual differences in DA functioning, and indeed in some ways may be a more 
relevant variable than receptor density examined in isolation  (as only available 
receptors can be engaged at a given point in time).                                                
Protocols for PET image acquisition and analysis were derived from a larger 
ongoing study and have been previously published 114, 115. Subjects received two 
PET scans using [18F]fallypride. The first scan was a baseline placebo scan; the 
second scan was performed while the subject received an amphetamine  (d-
AMPH) challenge. We used a single-blind drug administration regimen for the 
majority of participants; however, we also included in our analyses 15 subjects who 
participated in the study during a pilot phase, and who were not blind to drug. To 
control for any confounding effect of between-group differences in blinding, blinded 
status was included as a nuisance covariate in all analyses. PET imaging was 
performed on a GE Discovery LS scanner located at Vanderbilt University Medical 
Center that was upgraded to a Discovery STE system during the course of the 
study. All subjects received their baseline and d-AMPH scans on the same 
scanner. To ensure the validity of combining data across scanners, we performed 
a voxel-wise analysis comparing DA release between the two scanners.  No 
clusters survived whole brain correction at t = 2.5  (lowest cluster-level p-value 
>.90).  Moreover, no differences were observed in our anatomical region of 
interest, the ventral striatum  (left and right VS; both p-values > 0.45). 25 
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participants were scanned on scanner 1, and 33/32  (rs1137101/rs1137100) 
participants were scanned on scanner 2. To account for any potentially 
confounding effect of between-group differences in PET scanner, scanner  (i.e. 
scanner 1 vs. scanner 2) was included as a nuisance covariate in our regression 
analyses. Following reconstruction both scanners had similar in plane and 
throughplane resolution.  [18F]fallypride was produced in the radiochemistry 
laboratory attached to the PET unit, following synthesis and quality control 
procedures described in US Food and Drug Administration IND 47,245.  Scans 
were timed to start 3 hours after 0.43mg/kg oral d-AMPH administration, which was 
timed to coincide with the period of peak plasma d-AMPH. 3-D emission 
acquisitions scans were performed following a 5.0 mCi slow bolus injection of 
[18F]fallypride  (specific activity greater than 3000 Ci/mmol). Serial scans were 
started simultaneously with the bolus injection of [18F]fallypride and were obtained 
for approximately 3.5 hours, with two 15-minute breaks for subject comfort. CT 
transmission scans were collected for attenuation correction prior to each of the 
three emission scans.  
 
Binding Potential Maps 
Each subject’s serial PET scans were first corrected for motion across 
scanning periods and then co-registered to the subject’s structural T1-weighted 
MRI image.  To determine the success of the coregistration in the midbrain, in a 
prior study of 34 subjects115 we manually labeled several landmarks around the 
midbrain, including the posterior edge of the right and left inferior colliculus, the 
 84 
anterior-most point of the right and left cerebral peduncle and the interpeduncular 
fossa at z = 10, and the inferiormost point of the supramammillary commissure. Of 
these 34 subjects, all but one showed excellent midbrain coregistration, with no tag 
varying by 2mm in any direction from the mean coordinate of the tag  (across these 
33 subjects, the mean distance in any direction from the average tag was 1mm for 
every tag examined). Given the spatial resolution of the PET images, this degree 
of misregistration is at the subvoxel level, and would have negligible impact on the 
results. 
Regional D2/D3 binding potential  (nondisplaceable; BPND) was calculated 
on a voxelwise basis using the full reference region method119, with cerebellum 
chosen as the reference region because of its relative lack of D2/D3 receptors120. 
Voxelwise kinetic modeling was executed using Interactive Data Language. Prior 
studies in our lab indicate that the reference region method produces binding 
potential estimates that are in close agreement with estimates derived from Logan 
plots 121 using a metabolite corrected plasma input function. Because [18F]fallypride 
binding values exhibit significant variability across different regions  (e.g., striatum 
vs. prefrontal cortex; PFC), we used variance estimates at the voxelwise level 
rather than the pooled variance used in typical parametric analyses 122. Individual 
images of percent-change in [18F]fallypride binding from placebo to amphetamine  
(representing percent-change in DA release) were created by subtracting each 
subject’s amphetamine scan from their placebo scan and dividing the resulting 
imaging by the placebo scan, using the “imcalc” image math routine in SPM5. 
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Region of Interest Analyses 
 As our own prior work – as well as that of others – indicates that stimulant-
induced DA release in the ventral striatum is a robust predictor of individual 
differences in trait risk factors for substance abuse63, 67, 69, 71, 320, 321, we limited our 
analysis of the effects of LEPR genetic variation on stimulant-induced DA release 
to the ventral striatum. To that end, we constructed an anatomical VS region of 
interest (ROI) by manually editing the striatum ROI derived from the LONI 
Probabilistic Brain Atlas 40  (LPBA40)125 according to the criteria outlined in 
Mawlawi et al.  (2001)126, 127. To permit subregion-selective assessment of LEPR 
genotype effects within the striatum, we parcellated the LPBA40 striatum ROI into 
4 additional striatal subregion ROIs: dorsal caudate rostral to the anterior 
commissure  (AC), dorsal putamen rostral to the AC, post-commissural caudate, 
and post-commissural putamen, also using previously described criteria126, 127. 
Percent-change values were averaged across all voxels within left and right VS 
ROIs to create a single percent-change value for each individual’s left and right VS 
ROI.   
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Personality Measures 
 Personality data were available for 43 participants with rs1137101  
genotype data and 42 participants with rs1137100 genotype data. Impulsivity was 
assessed with the 30-item Barratt Impulsiveness Scale, version 11  (BIS-11)206, 
which is one of the most widely used self-report measures of impulsive personality 
traits207-216. The BIS-11 yields scores for 6 subscales  (Attention, Motor, Self-
Control, Cognitive Complexity, Perseverance, and Cognitive Instability) and 3 
factor scores  (Attentional, Motor, Non-Planning), as well as a full-scale score. We 
used full-scale scores only for correlation analyses.  Mean  (standard deviation) 
and range of BIS-11 scores for the rs1137101 sample: 58.35  (9.47), 43-84. Mean  
(standard deviation) and range for the rs1137100 sample: 58.74  (9.33), 43-84. 
The PPI comprises 187 multiple-choice items, and yields a total score, as well as 
Figure 1. Striatal Regions of Interest (ROIs). ROIs rendered on a T1-
weighted reference image, with a coronal slice at Y = 11 (MNI space). 
ROIs defined by anatomical criteria of Mawlawi et al (2001). Only pre-
commisural ROIs are shown.   
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scores for eight subscales: Impulsive Nonconformity, Blame Externalization, 
Machiavellian Egocentricity, Carefree Nonplanfulness, Stress Immunity, Social 
Potency, Fearlessness, and Coldheartedness. Based on the work of Benning and 
colleagues, and as reported previously in our work 63, 217, Impulsive-Antisocial  
(PPI-IA) factor scores were obtained by summing z-scores for the Machiavellian 
Egocentricity, Blame Externalization, Carefree Nonplanfulness, and Impulsive 
Nonconformity subscales. For the rs1137101 sample, mean  (standard deviation), 
and range for each of the scales comprising the PPI-IA score were: 62  (11.79), 
40-87  (Machiavellian Egocentricity); 28.35  (6.58), 19-41  (Blame Externalization); 
34.95  (6.72), 23-51  (Carefree Nonplanfullness); 34.91  (8.1), 22-57  (Impulsive 
Nonconformity). For the rs1137100 sample, mean  (standard deviation), and range 
for each of the scales comprising the PPI-IA score were: 62.4  (12.27), 40-89  
(Machiavellian Egocentricity); 28.67  (6.76), 19-41  (Blame Externalization); 35.12  
(6.8), 23-51  (Carefree Nonplanfullness); 34.93  (7.82), 22-56  (Impulsive 
Nonconformity). 
 
Statistical Analysis 
Statistical analyses using were performed using SPSS 17.0 for the 
Macintosh. To test for genotype effects on VS DA release, we used two linear 
regression models with rs1137100 and rs1137101 genotypes  (dummy coded as 1 
= A/A, 2 = G-carriers) as separate predictors of % change in DA release  (separate 
models for left and right VS). For each ROI, we used the mean percent-change in 
DA release value averaged across all voxels within that ROI  (described above). 
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PET scanner, ethnicity, and sex were included in the regression model as 
nuisance covariates. In follow-up control analyses, we added blinding status and 
VS BPND  as additional nuisance covariates. Two-tailed tests were used, with alpha 
= 0.05.  
To test for genotype effects outside of our primary VS region of interest, we 
performed two multivariate analyses of covariance (MANCOVA) using LEPR 
genotypes as predictors of AMPH-induced DA release within left and right VS, 
dorsal caudate, dorsal putamen, post-commisural caudate, and post-commisural 
putamen  (ROI creation described above). Sex, ethnicity, PET scanner and 
blinding status were included as nuisance covariates. 
Whole-brain genotype-effect analyses were performed using SPM5 running 
on Matlab R2007b for the Macintosh. We used two linear regression models with 
LEPR rs1137100 and rs1137101 genotypes (dummy coded as 1 = A/A, 2 = G-
carriers) as predictors of voxelwise DA release (i.e. we used voxelwise images of 
percent-change in DA release following AMPH administration, as described 
above). Scanner, ethnicity, blinding status and sex were included as nuisance 
covariates. To test for genotype effects, we used an uncorrected exploratory 
threshold of p < 0.005, coupled with a cluster-extend threshold of 20 voxels.  
We used four MANCOVA analyses to investigate the impact of LEPR 
genotype on impulsive temperament. For the BIS-11 analyses, LEPR rs1137100 
and rs1137101 genotypes were included as separate predictors of BIS-11 total, 
subscale  (Attention, Motor, Self-Control, Cognitive Complexity, Perseverance, and 
Cognitive Instability) and factor scores  (Attentional, Motor, Non-Planning), with sex 
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and ethnicity included in the model as nuisance covariates. For the PPI analysis, 
LEPR rs1137100 and rs1137101 genotypes were included as separate predictors 
of PPI total, subscale  (Machiavellian Egocentricity, Social Potency, Fearlessness, 
Coldheartedness, Impulsive Nonconformity, Blame Externalization, Carefree 
Nonplanfulness, and Stress Immunity) and the PPI-IA factor scores, with sex and 
ethnicity included in the model as nuisance covariates. For both analyses, two-
tailed tests were used, with alpha = 0.05. Reported p-values obtained from the test 
of Between-Subjects effects.  
 To test our hypothesis that sensitized VS DA release mediated the 
relationship between LEPR rs1137100 genotype and impulsive traits, we estimated 
the indirect of genotype on PPI-IA and BIS-11 scores through left and right VS DA 
release using a nonparametric approach as outlined in Preacher et al (2008)322, 
and implemented in the SPSS macro indirect.sbs. We tested four mediation 
models: for each model LEPR rs1137100 was used as the predictor (X) of BIS-11 
(Y1) or PPI-IA scores (Y2), using left VS DA (M1) or right VS DA (M2) as a 
mediator. Thus, the four models were: 1) XM1Y1, 2)XM2Y1, 
3)XM1Y2, and 4)XM2Y2. For each model, sex, ethnicity and PET scanner 
were included as nuisance covariates, and a bootstrap resampling procedure 
(5000 resamples) was used to generate point estimates of and 95% confidence 
intervals for each indirect effect (bias corrected and accelerated).  
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Results 
Descriptive and inferential statistics for VS BPND and AMPH-induced DA 
release 
For the rs1137101 sample, mean baseline BPND in the left and right VS 
ROIs were 21.89  (3.57) and 20.89  (3.69). Mean post-AMPH BPND values in the 
left and right VS ROIs were 20.7  (3.73) and 19.86  (3.66). For the rs1137100 
sample, mean baseline BPND in the left and right VS ROIs were 22.11  (3.75) and 
21.09  (3.81). Mean post-AMPH BPND values in the left and right VS ROIs were 
20.86  (3.82) and 20.02  (3.72). Repeated-Measures Analysis of Variance  
(ANOVA) confirmed a significant reduction in BPND in both left and right VS 
following AMPH administration  (rs1137100 sample: p = .00000003, left VS and p 
= 0.0000003, right VS; rs1137101 sample: p = .000000026, left VS and p = 
0..00000024, right VS) (Figure 2).  
 
Figure 2. Amphetamine significantly reduced [18F]fallypride binding potential in 
ventral striatum. Binding potential (BPND) values on placebo (PLAC) and 
amphetamine (AMPH) depicted for left and right ventral striatum for 59 participants 
with dual-scan PET data.  
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LEPR Genotype effect on VS DA release 
To test for an association between LEPR genotype and AMPH-induced DA 
release, we regressed LEPR genotypes against mean percent-change AMPH-
induced DA release values calculated from left and right VS ROIs. These analyses 
revealed a significant effect of rs1137100 genotype on AMPH-induced DA release 
in both left  (β = 0.34, p = 0.015) and right  (β = 0.43, p = 0.002) VS, such that G-
carriers showed significantly greater DA release in response to AMPH compared to 
A/A individuals (Figure 3). However, AMPH-induced DA release did not vary as a 
function of rs1137101 genotype in either left or right VS  (both p’s > 0.1). We did 
not find a significant effect of LEPR genotype on baseline D2/D3 binding in either 
left or right VS for either rs1137100 or rs1137101  (p-values for rs1137100 > 0.8; 
p-values for rs1137100 > 0.1). Importantly, rs1137100 remained a significant 
predictor of AMPH-induced DA release even when controlling for baseline VS 
D2/D3 levels  (i.e. baseline left and right VS BPND included as a nuisance 
covariate; left VS, p = 0.017; right VS, p = 0.002).    
 
Figure 3. Effects of LEPR rs1137100 genotype on AMPH-induced DA Release 
in left (A) and right (B) ventral striatum. Error bars indicate ± 1 standard error 
of the mean.  
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Striatal subregional specificity of LEPR genotype effects 
 While our a-priori hypothesis centered on a potential impact of LEPR 
genetic variability in VS, we endeavored to test empirically the subregional 
selectivity for LEPR rs1137100 effects within the striatum ( left and right VS, dorsal 
caudate, dorsal putamen, post-commisural caudate, and post-commisural 
putamen). This analysis revealed nominally significant effects in post-commisural 
putamen  (left VS, p = 0.012; right VS, p = 0.041) and left dorsal putamen  (p = 
0.047); however these did not survive a false-discovery rate correction for multiple 
comparisons218. We did not find even nominally significant effects of rs1137100 
genotype on AMPH-induced DA release in any of the other ROIs  (p-value range: 
0.06-0.53). We did not observe an impact of rs1137101 on any of these additional 
striatal ROIs  (p-value range: 0.08-0.76).  
 
Whole brain exploratory analysis 
To examine unhypothesized effects of LEPR genotype outside of our a-
priori VS ROIs, we performed a whole-brain regression analysis in SPM5. At a 
liberal, uncorrected exploratory statistical threshold  (p < 0.005 with a cluster-
extent threshold of 20 voxels), we did not observe any extrastriatal voxels in which 
AMPH-induced DA release was significantly predicted by either rs1137100 or 
rs1137101 genotype. In addition, we investigated the impact of LEPR genetic 
variation on baseline D2/D3 binding. At the same exploratory threshold noted 
above, we found no significant effect of variability at the LEPR loci on D2/D3 
binding potential anywhere in the brain.  
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BMI Correlation Analyses 
 Across both the rs1137101 and the rs1137100 samples, BMI ranged from 
17.5-30.6, with means  (standard deviations) of 23.38  (3.39) and 23.21  (3.35), 
respectively. Further, the distribution of BMI values was significantly right-skewed 
in both samples  (Figure 4), indicating that that the majority of participants were of 
normal weight. Despite this fact, 12 participants in the rs1137100 group and 13 
participants in the rs1137101 group met criteria for overweight  (BMI ≥ 25 kg/m2) 
and 1 person  (the same individual) in each group met criteria for obesity. 
Therefore, we were interested in determining whether BMI variation in this range 
was associated with either LEPR genotype or AMPH-induced VS DA release.  
Partial correlation analysis  (controlling for sex and PET scanner – all participants 
with BMI data were blind to AMPH administration) showed that AMPH-induced DA 
release was not associated with DA release in either left or right VS in both the 
rs1137101  (p = 0.54, left VS; p = 0.91, right VS) and rs1137100 groups  (p = 0.45, 
left VS; p = 0.83, right VS). In addition, neither rs1137101 or rs1137100 genotypes 
were significant predictors of BMI  (p’s = 0.61 and p = 0.74, respectively; adjusted 
for sex and ethnicity). 
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LEPR genotype and Impulsive Temperament 
 Prior work has demonstrated a shared propensity toward impulsive and 
novelty seeking traits in both obese and substance-abusing individuals. These 
same traits have been shown by our group and by others to be linked to enhanced 
stimulant-induced striatal DA release. Thus, the present finding that LEPR 
rs1137100 G-carriers showed relatively exaggerated AMPH-induced DA release 
within VS raised the possibility that LEPR rs1137100 genotype is also associated 
with impulsive traits. To test this notion, we examined the association between 
LEPR rs1137100 genotype and scores on the Barratt Impulsiveness Scale -11  
(BIS-11) and Psychopathic Personality Inventory, two measures that are both 
sensitive to risk for addiction and which independently predict individual variation in 
striatal DA reactivity in response to AMPH. LEPR rs1137100 genotype was a 
significant predictor of variability in BIS-11 total scores  (p = 0.02) and PPI 
impulsive-antisocial  (PPI-IA) factor scores  (p = 0.001). In both cases, G-carriers 
showed higher scores on these measures. Intriguingly, post-hoc control analyses 
Figure 4. Distributions of BMI values for the rs1137100 (A; n = 42) and 
rs1137101 (A; n = 43) samples.  
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revealed that the relationship between LEPR genotype and impulsive temperament 
was somewhat specific to impulsive-antisociality: while the relationship between 
rs1137100 genotype and PPI-IA scores remained significant after controlling for 
BIS-11 scores  (p = 0.02), rs1137100 genotype was no longer a significant 
predictor of BIS-11 scores after controlling for variation in PPI-IA scores, (p = 
0.44).  
 
LEPR Genotype, Striatal DA release and Impulsivity: Mediation Analyses 
 As mentioned above, we have shown previously that the magnitude of 
AMPH-induced striatal DA release is a significant positive predictor of impulsivity 
and impulsive-antisociality as measured by the BIS-11 and PPI63, 71. Here, we find 
that LEPR rs1137100 G-carriers show increased impulsivity and impulsive-
antisociality, and increased AMPH-induced DA release in ventral striatum. Taken 
together, these findings raise the intriguing possibility that genetic variability in 
leptin signaling  (as indexed by LEPR rs1137100 genotype) modulates impulsive 
temperament through an impact on striatal DA reactivity. As an initial test of this 
hypothesis, we performed correlation analyses to replicate in the rs1137100 
sample our prior finding of an association between AMPH-induced VS DA release 
and impulsive traits. Consistent with our prior work  (in sample that partially 
overlaps the one reported in this chapter), we found a significant correlation 
between ventral striatal DA release following AMPH administration and BIS-11 
scores  (r = 0.32, p = 0.045, left VS; r = 0.43, p = 0.006, right VS) and PPI-IA 
scores  (r = 0.39, p = 0.013, left VS; r = 0.53, p = 0.001, right VS); all p-values 
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adjusted for sex and PET scanner. To confirm our hypothesis that enhanced 
striatal DA release mediates the relationship between genetic variation in LEPR 
and impulsive traits, we next performed a series of mediation analyses.  
 First, we tested the significance of the indirect effect of LEPR genotype on 
BIS-11 scores through left and right VS DA release322. For left VS, the point 
estimate of the indirect effect was 1.227; however, the 95% confidence interval  
(C.I.) for this effect was -0.587 – 5.389, and we therefore cannot conclude that this 
effect is not significantly different from zero. For right VS, the point estimate of the 
indirect effect was 2.31, with a 95% C.I. of 0.366 – 6.884, confirming that this effect 
was significantly non-zero. We then performed the same tests of mediation 
employing PPI-IA scores as the dependent measure. For left VS, the point 
estimate of the indirect effect was 0.4672; however, the 95% confidence interval  
(C.I.) did cross zero  (-0.022 – 1.596), and we therefore cannot conclude that this 
effect is not significantly different from zero. For right VS, the point estimate was 
0.842, with a 95% C.I. of 0.107 – 1.991, permitting us to claim that this effect is 
significantly non-zero. Thus, the analyses indicate that the effect of LEPR 
rs1137100 genotype on impulsive and impulsive-antisocial traits is due, in part, to 
the sensitizing effect of carrying a G-allele on striatal DA reactivity  (though this 
effect – while statistically compelling for right VS – is merely suggestive for left VS)  
(Figure 5).  
  97 
 
 
Discussion 
Prior research has strongly implicated genetic variation in leptin – a critical 
biological mediator of feeding-related activity – as a susceptibility factor for obesity 
and obesity-related morbidity  (e.g. Type-II diabetes and hypertension)299-318.  
While such associations have typically been presumed to be a consequence of 
altered leptin signaling on homeostatic feeding processes mediated by the 
hypothalamus281, an alternative perspective is offered by recent preclinical work 
showing strong effects of leptin on mesolimbic DA circuitry for reward and 
motivation264. Here, we report the novel finding that genetically mediated variability 
in leptin signaling in humans predicts individual differences in impulsivity by 
Figure 5. Striatal dopamine sensitization mediates the impact of LEPR genotype 
on impulsivity. Path a shows coefficients for the effect of LEPR rs1137100 
genotype on right VS AMPH-induced DA release. Path b shows the coefficients 
for the effect of striatal DA on impulsive traits (PPI-IA/BIS-11). Paths c and c’ 
show coefficients for the total (dashed line) and direct (solid line) effects of LEPR 
genotype on impulsivity. All coefficients standardized.  
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sensitizing striatal DA responses to a psychostimulant drug of abuse. This finding 
supports the notion that leptin’s involvement in human feeding behavior is 
mediated through an impact on mesolimbic DA reward circuitry, as suggested by 
prior functional imaging studies of food reward298. Critically, we show for the first 
time that genetic variation in leptin affects human DA function, and does so in 
response to a non-food reinforcer – in particular, to a drug of abuse. Insofar as 
impulsive traits and exaggerated DA responses to stimulant drugs are markers of 
risk for addiction63, 68, 71, the present findings raise the intruiging suggestion that the 
LEPR variant studied herein may act pleiotropically to influence both addiction and 
obesity, and may do so through a common sensitizing influence on the mesolimbic 
DA reward pathway.    
Leptin was first recognized as a regulator of feeding behavior by genetic 
dissection of spontaneously obese  (ob/ob and db/db) mice, which were found to 
possess highly penetrant mutations in the murine Lep and Lepr genes281, 283, 287-289. 
Typically, these mutations produce a truncated leptin receptor protein that lacks a 
functional intracellular domain281, 287, 288. Analogous human mutations – also 
producing a truncated form of the leptin receptor – have been identified by 
sequencing in families with a multigenerational phenotype of severe, early-onset 
obesity: approximately 10 such rare mutations in the human LEPR gene have 
been reported, each causing congenital leptin deficiency293-295. Notably, a 
functional magnetic resonance imaging  (fMRI) study in two LEPR mutation 
carriers showed a heightened striatal response to food during a leptin deficient 
state, which was normalized by the acute administration of leptin298. Further of 
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note, striatal hyper-reactivity due to leptin deficiency was, in that study, linked to 
exaggerated subjective craving for food that persisted even after feeding298. 
Together, these studies suggest that genetically determined differences in leptin 
signaling affect feeding behavior in humans by altering brain responses to food 
stimuli within neural circuitry subserving reward and motivation.   
In contrast to the few highly penetrant, rare mutations described above – 
many of which are only found in a small number of consanguineous families – 
many common variants in LEPR have been identified, and several of these have 
reasonably consistent associations to obesity and obesity-related morbidity298. In 
the present work, we studied two of the most thoroughly examined variants, 
rs1137101 and rs1137100, both of which are nonsynonymous coding SNPs 
located within the LEPR gene (Figure 6).  The human LEPR gene is comprised of 
20 exons, and spans approximately 70kb of DNA on chromosome 1p31319, 323. 
rs1137101 is an AG SNP at position 668 in exon 6, causing an arginine to be 
substituted for a glutamine at codon 223  (Q223R; Gln223Arg)319, 323.  rs1137100 is 
an AG transition at position 326 in exon 4, resulting in lysine to arginine 
substitution at codon 109  (K109R;Lys109Arg) 319, 323 (Figure 5). 
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A number of studies have previously reported statistically significant 
associations between both of these SNPs and variation in BMI and obesity; related 
physiological variables such as fat mass, insulin levels, blood pressure; and related 
morbidity including type-II diabetes and early athersclerosis301, 306, 309, 324-329. 
However, this literature is far from consistent, and – like most association studies 
of complex, multifactorial phenotypes  – is rife with nonreplications and 
inconsistencies with respect to which allele confers risk. That said, there appears 
to be a trend in the literature  (especially in studies with younger and relatively 
Figure 6. Segment of the LEPR gene on chr.1 that includes exons 4-6. The positions of 
the rs1137100 and rs1137101 are highlighted (* = rs1137100, # = 1137101), and their 
genomic position is indicated with a blue arrow. The linkage disequilibrium structure of 
this region is depicted in the lower part of figure.  
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healthier subject 306) toward association of the G alleles at these SNPs  (i.e. 
109Arg and 223Arg) with risk.  
This pattern of association  (i.e. G as risk allele) would be consistent with a 
recent genome-wide study of soluble leptin receptor levels by Sun and colleagues  
(2010). Several leptin receptor isoforms have been identified: these share common 
extracellular and transmembrane domains, but differ in the length of the 
intracellular domain330, 331. A long form is expressed primarily in brain – most 
notably in hypothalamus, but also in tyrosine hydroxylase containing neurons of 
the dopaminergic midbrain290, 291 – while several short forms are variably 
expressed in peripheral tissue330, 331. In addition, a soluble isoform exists  (sOB-R), 
which lacks both the transmembrane and intracellular domains332. Notably, sOB-R 
levels strongly predict cell-surface expression of the leptin receptor  (in 
periphery)333, and are inversely correlated with adiposity, insulin resistance, and 
other risk factors for Type-II diabetes334-338. In their genome-wide association study 
with sOB-R levels, Sun and colleagues  (2010) found strong evidence for 
association between a number of LEPR SNPs and sOB-R levels, most notably 
rs1137101  (p = 1.91 X 10-10) and rs1137100  (p = 1.71 X 10-10)339. In both cases, 
the minor  (G) allele was associated with dose-dependent decreases in sOB-R 
levels.  Thus, for both rs1137101 and rs1137100, arginine substitution at these loci 
may lead to lower sOB-R and lower cell-surface expression of membrane-bound 
leptin receptors, which may explain in part the associations to obesity and related 
morbidity in G-allele carriers.  
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Crucially, if the putative link between LEPR genotype and cell-surface 
expression of leptin receptor holds in brain, this could account for our observation 
that 109Arg carriers have sensitized ventral striatal DA responses to stimulant 
administration and higher levels of impulsive traits. There is considerable evidence 
that leptin acts via midbrain leptin receptors to diminish the reward value of 
reinforcers291, 340, 341, and that this effect may be due in part to alterations in striatal 
DA output292, 340. A series of landmark studies provide a compelling demonstration 
of leptin’s role in attenuating reward responsiveness: leptin administration was 
found to reduce brain stimulation reward342, can block stress-induced 
reinstatement of heroin-seeking behavior343, inhibits the development of 
conditioned place-preference for palatable food and self-administration of sucrose-
reward344, and attenuates basal and feeding-evoked DA levels within the NAcc345.  
Furthermore, the impact of leptin on reward motivation appears to be 
specifically mediated by its actions on functional leptin receptors located in the 
dopaminergic midbrain.  Leptin receptor expression and tyrosine hydroxylase  (a 
marker of dopamine neurons) are extensively colocalized within the VTA291, and 
specifically in VTA DA neurons that project to the nucleus accumbens290. In one 
elegant study, Hommel and colleagues showed that direct intra-VTA administration 
of leptin inhibited feeding without affecting locomotor activity generally, and 
established – in vitro and in vivo – that leptin decreases VTA neuron excitability  
(i.e. lowered firing rate and action potential frequency). Critically, using a VTA-
specific conditional knockdown approach, these authors showed that selectively 
reducing VTA leptin receptor expression potentiates feeding behavior by 
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enhancing the animal’s preference for high-fat food consumption291. Subsequent 
work using this same approach showed that midbrain-selective knockdown of 
LEPR expression enhanced effort-based, instrumental responding for sucrose 
reward  (i.e. increased breakpoint on animals maintained on a progressive ratio for 
sucrose)346. Of note, midbrain LEPR knockdown also rescued the reduction in 
NAcc DA levels seen in animals maintained on a high-fat diet, suggesting that 
midbrain leptinergic signaling may have functional effects on mesoaccumbens DA 
circuitry346. It must be said that, in some regards, these effects are contrary to 
those reported in prior studies in congenitally leptin-deficient mice. For example, 
Fulton  (2006) reported that ob/ob have reduced VTA TH levels, attenuated 
locomotor responses to amphetamine and significantly diminished sensitization 
following a course of amphetamine treatment, all of which were reversed by leptin 
administration290. Moreover, these same mice were found in vitro to have lower 
levels of synaptic DA release in NAcc following electrical stimulation. However, 
these findings may result from compensatory changes in leptin receptor levels in 
these leptin deficient animals  (leptin receptor expression is upregulated in ob/ob 
mice347-349), and moreover, a subsequent study found no changes in stimulant-
induced locomotion or either baseline or stimulant-induced NAcc DA levels in vivo 
in ob/ob mice350.   
On the whole, the findings provide support for the idea that lowered LEPR 
expression in mesolimbic DA circuitry may enhance the incentive salience of 
rewards. Though speculative, it is possible that the effects of allelic variation at the 
human rs1137100 locus – previously associated with lower soluble leptin receptor 
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levels339, a marker for cell-surface leptin receptor expression  (at least in 
periphery)333 – on NAcc DA function that we report here are due to leptin receptor-
mediated alterations in mesoaccumbens DA reactivity. If the LEPR 109Arg variant 
is in fact associated with lower midbrain leptin receptor expression, one could 
predict that carriers of the 109Arg allele might show relatively impaired midbrain 
leptinergic signaling, resulting in a relative release from the inhibitory influence of 
leptin on midbrain neuron excitability. This enhanced VTA excitability could 
potentiate DA efflux in terminal field regions – including ventral striatum – following 
exposure to a pharmacological or natural reward. This relative augmentation in 
striatal DA release could, in analogy to the finding of increased instrumental 
responding for reward in Lepr knockdown animals346, enhance reward sensitivity 
and promote maladaptive reward-seeking behavior, accounting for our finding of 
higher impulsivity in 109Arg individuals. However, empirical support for this 
hypothesis will require significant future study.  
 In this chapter, we offer the first report that genetic variation in leptin, a key 
regulator of feeding and obesity, affects striatal DA responses to a stimulant drug 
of abuse and is associated with individual differences in trait risk factors for 
addiction. Insofar as these data demonstrate that genetic risk for obesity is linked 
to markers of risk for addiction (i.e. striatal hyper-reactivity and impulsive traits), 
this work provides support for the notion that the striking psychological and 
neurobiological commonalities between addiction and obesity may have its roots in 
shared genetic diathesis. We believe that the pathophysiological overlap between 
addiction and obesity, in concert with the current data, suggest a model of risk 
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whereby shared genetic susceptibility factors sensitize dopaminergic circuitry for 
incentive motivation to promote reward-seeking behavior. This sensitization may 
catalyze the transition from pleasure-based consumption of an hedonically valued 
substance  (a palatable food or drug) to a form of stimulus-driven, compulsive and 
habitual intake that is insensitive to devaluation and which persists despite 
significant adverse consequences  (i.e. addiction).   
Given the known importance of dopamine for feeding351, recent evidence of 
its involvement in obesity271, 352-354, and the findings of neurobiological overlap 
between obesity and addiction described above247, some investigators have begun 
to look at a role for addiction-associated variants in DA genes in predisposing 
maladaptive feeding behavior and obesity. We believe that the current data 
validate this approach, and further, serves to nominate genetic risk factors for 
obesity as candidates for enhanced phenotypic investigations in addiction.  
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CHAPTER V 
 
SUMMARY AND CONCLUSION 
 
 The purpose of this final chapter is threefold. First, I will summarize the 
aims and principal findings of each chapter  (II-IV), and will contextualize these 
findings within current neurobiological models of substance abuse. Second, I will 
detail some key specific limitations of the work presented herein, and some 
general limitations associated with the overall experimental methodology 
employed in this dissertation. Finally, I will discuss future directions for this line of 
research, and will address this discussion particularly towards overcoming some 
of the limitations that are inherent in current experimental approaches to 
understanding the neurogenetic architecture of psychiatric illness.   
 
Chapter II: Allelic Variation in the Dopamine Regulating Gene CSNK1E 
Sensitizes Stimulant-Induced Striatal Dopamine Release 
 Addiction involves a transition from initial “recreational” or pleasure-based 
use of a drug, to a state of compulsive and habitual drug taking that persists 
despite severe adverse consequences.  While many people are exposed to 
drugs of abuse, relatively few continue using drugs for long enough that they 
move beyond that initial pleasure-based stage to addiction4. One determinant of 
whether or not an individual makes the transition from early-stage recreational 
drug use to compulsive drug abuse appears to be their initial subjective 
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experiences of the drug – in particular, the degree to which they rate the drug 
effects as pleasurable or positive72, 75. This accords nicely with a wealth of 
preclinical data: rats also show significant individual variability in whether they 
develop addiction-like behaviors after being exposed to a drug of abuse. While 
animals cannot provide direct information about their subjective experiences, one 
strong predictor of liability to addiction is their behavioral responses to the initial 
administration of a drug21, 22, mirroring human findings. Moreover, in both animals 
and humans, subjective and behavioral responses are under the influence of 
genetic factors78, 80, 107, suggesting that individual differences in drug responsivity 
may contribute to the known heritability of addiction.5, 6.  
In this chapter, I examined one specific genetic factor – an allelic variant in 
the Casein Kinase 1 (epsilon) gene – with a prior positive association to positive 
subjective responses to psychostimulants. Given previous work by myself and by 
others indicating that subjective responses to stimulants are linked to enhanced 
dopaminergic transmission within the ventral striatum71, 124, we hypothesized that 
the allele linked to greater subjective positive responses to amphetamine would 
be associated with a higher magnitude ventral striatal DA release following 
amphetamine administration. This hypothesis was confirmed: rs135745 C-allele 
carriers showed significantly stronger DAergic responses to AMPH within the 
ventral striatum. Of note, the effect of genotype on DA release was selective for 
VS and did not extend into more dorsal regions of the striatum. In addition, we 
tested for an effect of CSNK1E rs135745 genotype on subjective responses to 
AMPH, but were unable to replicate the prior findings of Veentra-VanderWeele, 
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likely due to the significantly smaller sample size here. However, we did 
demonstrate that AMPH-induced DA release within VS significantly predicted 
subjective craving responses for AMPH, indirectly linking CSNK1E to risk for 
addiction. These results suggest that genetic variation in CSNK1E – by 
sensitizing striatal DA reactivity to drugs, leading to stronger subjective 
responses – may play a role in promoting the transition to addiction from early 
stage drug use.   
 
Chapter III: Genetic Variability in HPA-axis Function Alters Human Striatal 
Dopaminergic Reactivity 
 Stress is one of the most robust environmental risk factors for substance 
abuse. Individuals with high levels of early life stress use drugs earlier and go on 
to develop addiction at higher rates150, 355, 356, and acute stress is the single most 
important predictor of relapse in abstinent drug users357. However, there is 
significant individual variability in stress-reactivity, and in the predisposing effects 
of stress on addiction. A large body of preclinical research suggests that the 
effects of stress on addiction risk are due to a sensitizing impact on mesolimbic 
DA circuitry227, 228, and are mediated by the effect of stress-linked alterations in 
hypothalamic-pituitary-adrenal  (HPA) stress hormones (e.g. corticotropin 
releasing hormone) on midbrain DA neuron firing and DA levels in terminal field 
projection sites, such as the nucleus accumbens  (NAcc)237, 238. This implies that 
genetic variation in HPA-axis factors could confer risk for addiction by affecting 
the responsivity of the mesolimbic DA system.  
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 In this chapter, I tested this hypothesis by examining the impact of an 
allelic variant in the corticotropin releasing hormone gene (CRH) on DA 
responses to AMPH. We found that an allele that has been previously reported to 
be under-transmitted to individuals with behavioral inhibition was associated with 
stronger DA responses to AMPH within the ventral striatum. Given the prior 
report of undertransmission to behaviorally inhibited subjects, we sought to test 
for an association between this allele and behavioral disinhibition. Though we did 
not find compelling evidence for such an association, enhanced VS DA 
responses to AMPH positively predicted scores on two trait measures of 
impulsive temperament. These findings support the notion that variability in HPA 
signaling may affect risk for substance abuse 200, 201, 225, suggest that such 
associations may be mediated through the sensitization of mesolimbic DA 
responses to drugs of abuse, and nominate CRH for more thorough investigation 
as a specific genetic risk factor for addiction.   
 
Chapter IV: Obesity-linked Genetic Variability in Leptin Signaling Predicts 
Alterations in Mesolimbic Dopamine Neurochemistry 
 Though traditionally considered a disease of nutrition and metabolism, 
obesity is increasingly recognized to have a strong psychological component. In 
particular, much of the recent focus on obesity as a psychological disorder 
centers on the striking psychopathological and neurobiological overlaps between 
obesity and addiction. For example, obese individuals show patterns of brain 
chemistry and function that are reminiscent of those seen in drug addicts247, 258. 
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This observation has led to several recent findings which suggest that previously 
identified genetic risk factors for addiction – particularly variants in genes that 
participate directly in DA signaling  – also play a role in the development of 
obesity, and may do so by impacting striatal reward circuitry270, 358-360. However, 
the possibility that obesity-linked genetic factors may affect dopaminergic 
function – thereby nominating them for enhanced phenotypic characterization in 
addiction – remains completely unexplored. 
 In this chapter, I examine the impact of two such variants – SNPs in the 
gene encoding a receptor for the energy-regulating hormone leptin  (LEPR) – on 
mesolimbic dopamine system function. Prior work suggests that leptin 
downregulates the activity of midbrain dopamine neurons by acting directly on 
midbrain-expressed leptin receptors, thereby reducing DA outflow in terminal 
field regions such as the striatum. Based on these findings I hypothesized that 
individuals carrying the G-allele at two LEPR SNPs, which have been linked 
previously to obesity and to reduced soluble leptin receptor expression, would 
show higher levels of striatal DA release in response to AMPH. This hypothesis 
was confirmed for G-allele carriers at one SNP  (rs1137100), but not the other  
(rs1137101). Individuals possessing a G at the rs1137100 locus  (causing a 
lysine to arginine substitution at codon 109) showed greater stimulant-induced 
DA release in ventral striatum. Further, these same individuals demonstrated 
higher levels of impulsive and impulsive-antisocial traits that have been shown 
previously to be associated with risk for addiction. These traits were correlated 
with the magnitude of stimulant-induced DA release within VS in this sample. 
  111 
Finally, using path analysis, I was able to show that the impact of genetic 
variation at the rs1137100 locus on individual differences in impulsive traits is 
mediated by the sensitizing effect of carrying G allele at that locus on stimulant-
induced DA release, which in turn positively predicts trait impulsiveness and 
impulsive-antisociality.  Taken together, these findings suggest that genetically-
mediated individual differences in leptin signaling may lead to obesity by 
impacting mesolimbic DA circuitry for reward and motivation. Critically, given the 
associations to trait risk factors for substance abuse, these data also argue that 
genetic variation in LEPR may also contribute to risk for addiction.  
 
General Discussion 
  The experiments detailed in this dissertation provide compelling evidence 
that the impact of genetic variation in diverse brain signaling pathways linked to 
risk for addiction converge to affect the reactivity of a final common 
neurobiological pathway: the mesolimbic dopamine system. Furthermore, there is 
a consistency in the directionality of the effect of the putative risk allele at each of 
the genetic loci under study herein. In each case, the allele that we hypothesized 
might confer risk for addiction – because of prior associations to enhanced 
subjective responses  (CSNK1E), to lower levels of behavioral inhibition  (CRH) 
or to obesity and to diminished leptin receptor expression  (LEPR) – was 
associated with enhanced striatal DA responses following the administration of a 
stimulant drug.  
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These findings are potentially important given a current debate among 
addiction researchers on the nature of altered dopaminergic function in addiction. 
On the one hand, several investigators have reported diminished dopaminergic 
reactivity in addicted invididuals  (DA hypofunction). For example, a number of 
studies have shown lowered D2 receptor availability and blunted stimulant-
induced DA release in cocaine, alcohol, and heroin dependence273-275, 361-366. 
Findings of lowered dopaminergic function have been taken by some as 
evidence for a primary deficit in reward processing in addicted individuals. 
According to this theory, diminished sensitivity to rewards due to dopaminergic 
hypofunction leads at-risk individuals to excessively seek out rewards – 
especially, drug rewards – to compensate for natively depressed dopaminergic 
tone.  
Lowered dopaminergic function as a consequence of neuroplastic 
adaptations associated with chronic substance abuse may well be responsible 
for drug-seeking behavior in active addiction or drug craving in recent 
abstinence. However, it is difficult to make inferences about etiopathophysiology 
from these data, as it’s impossible to know whether PET markers of 
dopaminergic hypofunction are a cause or consequence of chronic substance 
abuse, given that chronic dosing with many drugs of abuse causes dramatic 
synaptic remodeling within mesolimbic reward circuitry367, 368.  Moreover, 
individuals with no history of drug abuse, but who nevertheless possess certain 
trait risk factors that robustly predict the development of addiction – such as 
novelty seeking and impulsivity – consistently show enhanced dopaminergic 
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function63, 67, 69-71, 369. Such findings accord well with animal data showing that the 
development of addiction is associated with striatal DA sensitization  (with 
attendant enhancement of the incentive salience of the drug of abuse, as 
detailed in the introduction), and with work demonstrating heightened striatal DA 
in animals at risk for developing addiction-like behaviors370, 371. In light of these 
data, and in consideration of the fact that traits like impulsivity and novelty 
seeking show significant heritability372-374, some have proposed that genetic risk 
for addiction is conveyed through dopaminergic hyper- (rather than hypo-
)sensitivity375.  
Importantly, to the extent that we show that three specific putative genetic 
risk factors for addiction lead to ventral striatal DA hyper-reactivity in individuals 
with no history of substance abuse, our data supports the DA hypersensitivity 
model of addiction liability. It is noteworthy that we are able to demonstrate that 
putative genetic risk factors in three distinct neurobiological pathways  (DA 
signaling, HPA-axis, energy-regulating hormone) have a common sensitizing 
effect on mesolimbic DA responses. Moreover, one of these putative risk variants  
(LEPR rs1137100) has strong support as a susceptibility factor for obesity, 
raising the intruiging suggestion that pleiotropic effects of leptin genetic variation 
on diverse forms of disinhibitory psychopathology  (addiction and obesity) may 
be mediated by a common influence on mesolimbic DA system function. Taken 
together, the present data provide critical translational evidence favoring a model 
of addiction etiology that holds enhanced striatal DA responses to reinforcers as 
its cornerstone375.    
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How might genetically mediated DA hypersensitivity act to confer risk for 
addiction? It may be that a sensitized striatal DA response during the early stage 
of recreational or pleasure-based drug use in risk-allele carriers promotes an 
excessive, inflexible, and long-lasting attribution of salience to drugs and drug 
cues.  In this way, striatal hyperdopaminergic could cause a hyper-attribution of 
salience to reward predicting cues through a pathologically accelerated form of 
Pavlovian learning, as would be predicted from Berridge and Robinson’s 
Incentive Salience theory of addiction. Further, after this learning has taken 
place, exposure to such a cue may establish an inflexible attentional focus on 
that cue, leading to the execution of behavioral routines that are associated with 
obtaining the drug. The resiliency of this attentional focus to interruption and 
updating by subsequent motivationally relevant  (but goal-irrelevant) information 
may be maladaptive. This account accords with the suggestion of Gruber and 
colleagues that excessive striatal DA might result in perseverative responding 
through an over-stabilization of task-relevant WM representations  (i.e. at the 
expense of flexibly updating WM representations to respond appropriately to 
subsequent salient events)376. Such a mechanism could explain how excessive 
striatal DA release in response to a motivationally significant cue could lead the 
overstabilization of cue-linked prefrontal goal representations centered on drug-
seeking. This overstabilization may impair the flexible redeployment of limited-
capacity attentional resources to other motivationally salient but task-irrelevant 
information that might otherwise adaptively modify behavior  (e.g. punishment-
predicting cues, or cognitive action-outcome associations derived from prior 
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experiences with drug-seeking behavior). In this manner, heightened striatal DA 
responses during early stage drug use in genetically at-risk individuals may 
facilitate the acquisition of maladaptive drug-related stimulus-response habits.  
The acquisition of such habits could promote compulsive drug use even after the 
development of tolerance to the positively-valenced subjective effects of the drug 
lead would otherwise lead to devaluation of the drug as a reinforcer.  
In general, our articulation of possible systems and synapse-level 
mechanisms that might underpin the impact of the genetic variants detailed 
herein on stimulant-induced DA release assume a “steady-state” effect of these 
variants on DA signaling. However, it is equally likely – even probable – that our 
observed effects are the result of enduring, compensatory neurobiological 
changes that are the result of a brain that matures in the altered developmental 
context induced by a risk variant. That is, the specific impact of a risk variant on 
VS DA release may not in fact be due to the way that such a variant alters the 
acute response of mesolimbic circuitry at the moment of amphetamine 
administration. Rather, the observed enhancement of striatal DA responses in 
risk-allele carriers may be a consequence of developmental changes in 
mesolimbic circuitry that fundamentally alter the response properties of that 
system.   
One well-known example of this phenomenon involves a variable number 
of tandem repeats (VNTR) polymorphism that resides in the upstream region of 
the serotonin transporter gene (commonly referred to as the 5HTTLPR). The 
“short” repeat allele at this locus is associated with lower transporter expression, 
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corticolimbic dysregulation, and increased risk for mood disorders such as 
depression. However, it was striking – and perplexing – that the allele that was 
associated with increased risk for depression led to a functional effect (enhanced 
synaptic serotonin, via reduced transporter cell-surface expression) that mirrored 
the primary neuropharmacological effect of first-line antidepressant drugs (i.e. 
serotonin-selective reuptake inhibitors). Insight into this apparent discrepancy is 
gained from studies by Gingrich and colleagues, who demonstrated a 
developmentally specific effect of increased serotonin levels on emotional 
behavior. Specifically, these studies showed that increasing serotonin levels 
pharmacologically in early development results in delayed and persistent 
changes in fear and anxiety behaviors in adult animals. Similar pharmacological 
manipulations in adult animals had no effects on these behaviors377, 378. These 
findings imply that the 5HTTLPR short allele affects serotonin signaling during a 
specific ontogenic window to affect the development and maturation of neural 
circuits that are implicated in mood and anxiety disorders, and that these 
developmental effects cause changes in the functional response of these circuits 
to affectively salient stimuli in adulthood379, 380.  
Similarly, the polymorphic variants studied in the current thesis may 
produce a striatal hyper-DA phenotype through developmental compensations. 
For example, as discussed in Chapter IV, leptin loss-of-function mutant (ob/ob) 
mice show a neurobehavioral phenotype that differs markedly from that 
generated by acute adult downregulation of leptin signaling. One noteworthy form 
of apparent developmental compensation in ob/ob mice is upregulation of 
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membrane-bound leptin receptor levels347, which may explain some of alterations 
in reward behavior and striatal DA function in these mutants. In anology, changes 
in the function or expression of CSNK1E, CRH, or LEPR could sensitize striatal 
DA function by inducing developmental compensations that lead to a lower 
reactive set-point for DA release following drug administration. Given that 
neurotrophic factors – in particular, TrkB – appear to play a criticai role in 
regulating mesolimbic DA circuit development381, 382, function383, 384, and 
responses to stimulant drugs385, 386, it is tempting to speculate that some of the 
effects of genetic variation in, for example, CSNK1E, may be mediated by 
intermediate effects on neurotrophin signaling. Given that CSNK1E, by impacting 
PP1 phosphorylation of voltage-gated ion channels and excitatory amino acid 
receptors, could influence striatal MSN membrane excitability, it seems possible 
that genetic variability at the CSNK1E locus could lead to enhanced MSN activity 
following exposure to a stimulus that leads to synaptic DA release. Enhanced 
MSN activity could, in turn, stimulate the expression of neurotrophic factors (such 
as brain-derived neurotrophic factor or BDNF), which may bind to presynaptically 
localized TRKB receptors. Retrograde neurotrophic signaling could then lead the 
propagation of this enhanced post-synaptic signal back through NAcc projecting 
axons of the VTA to influence mesolimbic circuit development. In this way, 
CSNK1E-mediated changes in post-synaptic MSN activity could, throughout the 
course of mesolimbic system development, lead to circuit and/or synapse-level-
remodeling that may explain the differential sensitivity to drug reward in risk allele 
carriers.   
 118 
Another aspect of our mechanistic proposals for the actions of 
polymorphic variation in CSNK1E, CRH, and LEPR on DA signaling is the 
assumption of “local” effects that only impact specific nodes within mesolimbic 
DA circuitry (i.e. VTA and NAcc). However, it is also possible that these variants 
exert primary effects at sites distal to our measured neurobiological end-point, 
and that our observed changes in mesolimbic DA are due to the ramification of 
these proximal effects outward onto mesolimbic circuit nodes. As one example, 
several lines of evidence point to the hippocampus as an important mediator of 
the effects of CRH signaling on behavior. For instance, CRH-expressing 
interneurons are prominently expressed in hippocampus, and – following 
exposure to a stressor – these neurons release CRH into intercellular 
hippocampal space, where it can bind to CRH1 receptors that are found 
abundantly on hippocampal pyramidal cell dendrites387-390. CRH action within the 
hippocampus is particularly intriguing in the context of our current findings given 
that this region plays a critical role in modulating dopamine neuron firing. In a 
series of elegant studies, Grace and colleagues have shown that only the pool of 
spontaneously active VTA neurons can be driven to burst firing by excitatory 
input, and that the size of this pool is determined largely by excitatory efferents 
from ventral hippocampus391-393. Thus, the hippocampus is well positioned to 
regulate VTA reactivity in response to rewarding stimuli. Of note, prior work 
demonstrated that stimulation of the ventral hippocampus leads to increased DA 
neuron activity, which is in turn correlated with increased extracellular DA within 
NAcc. Therefore, risk-allele associated alterations in CRH signaling within 
  119 
hippocampal pyramidal neurons could impact glutamatergic inputs to DA 
midbrain neurons, which in turn may enhance the reactivity of these neurons, 
increasing DA release within terminal field regions (such as NAcc) in response to 
stimulation. Overall, significant future work is required to definitively identify the 
proximal causal site of action of the polymorphisms under study in this thesis. In 
the case of CRH, regionally specific conditional over-expression in concert with 
pharmacological stimulation and amperomic/voltametric recording of NAcc DA 
release events may be one fruitful avenue of research.    
Limitations and Future Directions 
The experiments presented in this dissertation share several significant 
limitations, and addressing these limitations presents an opportunity for 
considering future directions for this research. First, the precise cellular and 
molecular-level consequences of variation at the three loci reported in this 
dissertation are essentially unknown. In the case of the CSNK1E and CRH 
SNPs, their positions in the 3’ UTR of those regions suggest the possibility that 
those base pair substitutions may affect miRNA target sites, which could 
conceivably affect protein expression levels by disrupting translational repression 
mechanisms. However, in silco prediction tools do not suggest that these specific 
substitutions would impact predicted human miRNA target sites 394. In the case of 
LEPR, rs1137100 is a nonsynonymous coding SNP, suggesting that its 
functional effect on DA release is due to alterations in the protein structure of the 
leptin receptor. However, this amino acid substitution – located in the 
extracellular domain of the receptor – is conservative  (does not result in a 
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change in charge), and is not predicted to have a dramatic or deleterious impact 
on function (PolyPhen: http://genetics.bwh.harvard.edu/pph/).  Another 
interpretation is that these SNPs are monitoring haplotype blocks that harbor true 
causative variants: this interpretation is particularly salient for the LEPR and CRH 
SNPs, which reside within segments of chromosome that are characterized by 
high linkage disequilibrium over several kilobases. On the whole, it must be said 
that a much finer genetic mapping of our association signals is required. Future 
studies might employ targeted sequencing of the CSNK1E, CRH, and LEPR to 
identify the true causative variants that may be driving our reported gene-brain 
associations.  
Our use of an ethnically heterogeneous sample also requires comment. In 
general, genetic associations studies that employ unrelated individuals face a 
problem in interpreting significant association signals when the sample includes 
individual of different genetic ancestry. Ethnically heterogeneous samples are 
problematic because differences in allele frequencies may exist between 
population segments that differ with respect the prevalence of a disorder or trait. 
Such differences may create spurious association signals if the effects of this 
population admixture are not accounted for in datasets where there is ethnic 
stratification across disease status or across levels of a quantitative trait395. Due 
to funding body requirements for racially inclusive subject recruitment, our study 
recruitment was blind with respect to ethnicity. Further, given the time and 
expense of acquiring dual-scan radioligand PET data  (8k-10k/subject), we were 
unable to acquire a sample that was large enough to permit us to exclude non-
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Caucasians from analysis. However, in each chapter, self-reported ethnicity was 
included as a nuisance covariate in all of our analyses, and all reported 
associations remained significant even after reanalyzing without non-Caucasian 
participants. That said, while some evidence does exist to support the notion that 
self-reported ethnicity matches genetically inferred ancestry396, there is important 
population substructure that is not easily resolvable at the level of self-report, and 
which could contribute to spurious associations397. Thus, we cannot definitively 
rule out the possibility that our findings may be influenced by the presence of 
cryptic population admixture. Future studies in ethnically homogenous samples, 
or those using ancestry informative markers (AIMS) and/or panels of unlinked 
markers  (genomic controls) to detect and correct for cryptic structure will useful 
in confirming the validity of the current findings.   
One potentially important consideration in interpreting the present data is 
our specific measure of DA release. While the drug-induced radiotracer 
displacement approach that we employ has been in wide use for nearly 20 years, 
it is fundamentally an indirect or proxy measure of stimulated DA release. As 
such, this measurement is vulnerable to influence by confounding factors that are 
unrelated to the principal phenomenon under study. For example, it is 
conceivable that the measures of individual differences in D2/D3 receptor used to 
compute our percent-change DA release images is contaminated by individual 
difference in tonic DA levels. Further, some have suggested that the reduction in 
[18F]fallypride binding potential following AMPH administration – presumed here 
to reflect displacement of [18F]fallypride by stimulant-induced increase in 
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endogenous synaptic DA – in fact results from an AMPH-induced internalization 
of D2-like receptors398. Thus, individual differences in receptor trafficking, rather 
than increased striatal DA release, may play some role in determining our DA 
release phenotype measure. In addition, it is striking that the effects of genetic 
variation in the three signaling systems under study in this thesis appear to have 
a relatively selective impact on ventral striatum. We do not have a compelling 
explanation for why this is the case, although it is noteworthy that ventral striatum 
receives stonger input both from VTA (which may have denser expression of 
CRH1 and LEPR receptors relative to the neighboring substantia nigra) and from 
limbic regions such as the amygdala. It is possible that differential input from 
limbic nuclei into ventral striatum may account for the higher level of individual 
variability in ventral striatal DA release, but this notion remains speculative. 
Finally, it must be noted that a specific mechanism to account for why, in the first 
instance, individual differences in this measure are observed at all, remains 
elusive. While we have shown previously that midbrain D2/D3 binding 
(presumably reflecting autoreceptor levels) can affect striatal DA release, other 
sources – including striatal DA transporter levels, presynaptic autoreceptor 
levels, changes in DA synthetic or catabolic enzymes – may certainly account for 
a significant proportion of the cross-subject variance in striatal DA release. Taken 
as a whole, it must be said that significantly more work needs to be done in order 
to effectively parse the origin of individual differences in our AMPH-induced 
[18F]fallypride displacement signal. 
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In considering the implications of our findings, it worth reflecting on the 
fact that the genetic variants under study in these experiments accounted for a 
relatively small proportion of the variance in ventral striatal DA responses to 
AMPH (12-20%). Thus, even if we take as granted that individual differences in 
DAergic function account for some of the variance in determining who becomes 
addicted, and assuming that subsequent studies of genetic association confirm a 
role for these variants in substance dependence, variability at the loci examined 
in this dissertation are likely to account only for a very small proportion of the 
variance in susceptibility to addiction.  This is akin to the situation in other 
psychiatric disorders, like schizophrenia, that have a moderate-high heritability, 
but for which common risk variant only account for a small proportion of variation 
in disease liability. This general issue has been termed the problem of “missing 
heritability,”399, 400 and would appear to challenge the common disease-common 
variant  (CDCV) hypothesis that underpins many approaches to the genetic 
dissection of complex psychological traits and disease, including those geared 
toward associating common genetic variants to neurobiological endophenotypes, 
as in this dissertation. Two possible explanations for this “missing heritability” are 
particularly worthy of mention here.  
Many investigators have noted that an approach that is geared toward 
examining the effects of single variants in isolation, without taking into account 
the larger biological context in which this variation takes place, will necessarily 
fail to account for a significant degree of variability in any phenotype, regardless 
of the penetrance of a genetic effect to that phenotype401, 402. Any single variant 
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in any one chromosome in any one individual occurs on a complex background 
of genetic variability, and that background may differ from individual to individual. 
One technique for resolving this background is to investigate epistatic 
interactions between multiple variants403. Epistatic interactions have been 
observed in risk for multiple somatic disorders, implying that they may be at play 
in risk for psychiatric phenotypes as well404, 405. Indeed, one recent study of 
schizophrenia used machine-learning algorithms to construct multi-marker 
genetic risk profiles from variation in three genes that have each been weakly 
associated with psychosis, and whose gene products are known to participate in 
the same biological signaling pathway. The authors showed that epistatic 
interactions between the three markers resulted in a dramatic increase in the 
amount of variance in risk explained, compared to any of the SNPs in isolation, 
and used brain imaging to confirm the presence of epistatic interaction effects on 
a measure of brain function linked to illness406, 407. These and other findings408-410 
strongly point towards the study of epistatic interactions within and between the 
biological pathways highlighted in this dissertation as an important direction for 
future research on the neurogenetic architecture of addiction.   
Another approach towards uncovering the missing heritability of complex 
diseases involves broadening the CDCV paradigm to account for the potential 
influence of rare, but highly penetrant, alleles on disease. Some investigators 
have even gone so far as to suggest that any observed association of a common 
variant to a disease or disease-linked phenotype is due to the fact that such 
common variation is incompletely tagging, or acting as a low-fidelity proxy 
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association signal for, causative rare mutations411, 412. To circumvent this issue, 
they recommend whole-genome sequencing to identify rare, causative mutations 
for psychiatric disorders in as yet unidentified genes413.  
However, others have taken a compromise approach to this issue by 
suggesting that the known pathobiology of a disorder is essential in guiding the 
selection of genes for targeted sequencing for rare variation. For example, 
Blakely and colleagues have found a number of highly functional coding variants 
in the dopamine transporter gene, which has long been implicated in the 
pathophysiology of disinhibitory psychopathology. Notably, these variants 
associate with attention deficity/hyperactivity disorder, a disinhibitory spectrum 
syndrome, confirming that an approach geared toward identifying rare, causative 
mutations in genes that are of a-priori interest based on known systems-level 
pathobiology may be a viable strategy for complementing studies of common 
variation in these disorders414-416. Furthermore, there are considerable 
opportunities for leveraging the strengths of this approach with those inherent to 
human neuroimaging. For example, the quantitative stimulant-induced DA 
release phenotype discussed in this dissertation can be used as a means of 
selecting participants for sequencing: we have evidence that a small proportion 
of individuals demonstrate anomalous striatal DA responses to AMPH that are 
exactly what would be predicted from carriers of some of these rare mutations415. 
On the whole, integrating the study of rare variation with human imaging 
phenotypes holds significant promise for elucidating a more complete picture of 
genetic risk for addiction.  
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One potentially promising future avenue of research involves using 
quantitative neuroimaging endophenotypes in the service of discovering novel 
genetic risk factors for addiction.  To date, there are relatively few robust, 
reliable, and well-replicated associations between specific genetic variants and 
addiction. I believe that the nonreplications and inconsistencies that plague 
psychiatric genetics are likely due to the manner by which we have traditionally 
tested for genetic associations. In identifying risk genes for disorders, the primary 
approach has always been some form of statistical association between specific 
genetic variants to taxonomic clinical diagnostic phenotypes. This can be done in 
a simple univariate fashion, as in candidate gene studies, or in a massively 
univariate or multivariate fashion, as in genome-wide association studies. 
In such studies – which can be either family-based or involve unrelated 
cases and controls – individuals are grouped according to diagnosis  (most 
commonly, “affected” and “normal”), and the frequency of a genetic marker is 
compared between the diagnostic groups. A statistically significant difference in 
the frequency of the transmission of a genetic marker to an ill sibling  (in family 
based studies) or in the frequency of that genetic marker between the groups  (in 
case-control studies) is taken as evidence of a positive genetic association. The 
strength of that association is can be considered in terms of  (as one example) 
an odds ratio, where a “risk” genotype is considered to confer a certain degree of 
increased susceptibility to that disorder, relative to the “non-risk” genotype. The 
problem here lies in the use of taxonomic clinical diagnosis as a phenotype. At 
the risk of stating the obvious, genes do not encode DSM-IV diagnoses: rather, 
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genes encode proteins, which form signal transduction pathways, which are 
wired together into circuits, which form large-scale neural systems, which 
process incoming sensory information and integrate and reconcile that 
information with internally generated goals to output adaptive behavior. 
Therefore, the proximal effect of a risk-associated genetic variant is not on a 
specific disorder – the conceptualization and boundary conditions of which are 
largely going to be socially constructed – but on protein structure, function and/or 
expression.  
Critically, it seems readily apparent that when we move away from gene 
from to protein to cell to systems to disease along the path outlined above, both 
our genetic complexity and our phenotypic complexity increase dramatically. For 
example, at the level of a single DSM-IV taxonomic disorder, there are likely to 
be multiple genes that interact, with each other and with environmental factors, to 
affect risk  (Figure 1).  
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Further, there may be distinct patterns of genetic linkages to heterogenous 
sub-phenotypes that exist within a single broad diagnostic taxon. That is, 
different sets of genes may be linked to risk for relatively distinct (and possibly, 
cryptic or latent) disorder subtypes that exist within a broad taxon. The net effect 
of this complexity is necessarily going to be diminished power to detect 
potentially meaningful genetic associations, as each step away from the direct 
biological impact of a genetic variant on protein production is going to weaken 
the strength of the potential association signal. However, the penetrance of 
genetic variant – the likelihood that any given individual with a certain genotype 
Figure 1. Genetic complexity of taxonomic disorders.  
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will express the associated phenotype – varies depending on the kind of 
phenotype being examined. It is thought that by studying intermediate 
neurobiological phenotypes, which are closer to the direct biological impact of the 
genetic variant under study, we are able to increase our ability to find an effect of 
genotype. Indeed, meta-analyses of imaging data confirm that the use brain 
imaging endophenotypes affords us increased genetic penetrance, larger effect 
sizes, and thus an increased likelihood of finding gene effects9, 417.  
Importantly, the fact that larger effect sizes are found for brain imaging 
endophenotypes suggests that we can use brain imaging as a deep phenotype to 
aid in gene discovery. Combining highly penetrant quantitative trait data with 
genome-wide genotyping opens up the possibility of using the genome-wide 
association study (GWAS) as a tool for both variant identification and 
pathomechanism characterization. Importantly, the enhanced effect size 
associated with imaging endophenotypes suggest that the number of subjects 
required for genome-wide significance will be dramatically fewer than the 5000-
10000 typically required for genome-wide significant associations to diagnosis. A 
recent study by Stein and colleagues demonstrates this point. Their GWAS 
identified a common glutamate receptor variant  (GRIN2b) that was associated 
with temporal lobe volume and increased risk for Alzheimer’s disease using 
structural MRI scans. Using an imaging phenotype, the authors identified 
variation in a gene that was not previously under consideration as a risk factor for 
Alzheimer’s, and characterized a mechanism through which it might affect risk418, 
419. Potkin and colleagues took a similar approach to gene identification using a 
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working memory task, and reported a novel association to prefrontal function with 
SNPs in the MYLIP gene. Given that prefrontal function in this task has been 
associated previously with risk for schizophrenia, this strategy nominates MYLIP 
as a novel genetic risk factor for prefrontal dysfunction in that disorder420, 421.  
These reports suggest a fruitful path forward in identifying novel risk 
factors for addiction: genome-wide studies with stimulant-induced striatal DA 
release as a phenotype measure. Sample sizes will likely need to be higher than 
the ones reported in this dissertation, but as the utility of PET imaging disease 
phenotypes are recognized, one might envision future studies of 100-200 PET 
subjects each at multiple sites with synchronized scanning protocols. In analogy 
to current efforts underway to identify Alzheimer’s risk genes, data from 1000-
1500 participants  (a likely lower bound on sample size required for genome-wide 
significance with imaging data, based on current effect size estimates) could be 
collected from these multiples sites over the course of five years. Such large-
scale, well-coordinated efforts will be required to advance target selection for 
medication development, a major goal for the neuroscientific study of addiction.  
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